

weillcornellmedicine



THE MAGAZINE OF
WEILL CORNELL MEDICAL
COLLEGE AND
WEILL CORNELL
GRADUATE SCHOOL OF
MEDICAL SCIENCES

FALL 2009

ANNUAL
REPORT ISSUE


The Age of Discovery

How Weill Cornell's
Scientific Minds
Are Advancing
Health Care

Brain Power



This recently converted 70,000-square-foot building on East 61st Street is the nexus of the Medical College's translational initiatives in accelerating discoveries into superior treatments for the Weill Cornell community and beyond. The 61st Street Science Building is now home to the Clinical and Translational Science Center (CTSC), which focuses on bench-to-bedside research and supports the activities surrounding the \$49 million grant Weill Cornell received from the National Institutes of Health (NIH). This initiative comprises and coordinates the efforts of eleven institutions in and around New York City and is the largest federal grant ever received by the Medical College.



The 61st Street Science Building also represents the first step in the Strategic Plan to drastically expand laboratory space at Weill Cornell. Notably, this new building has devoted two floors to the Division of Neurobiology Research and will be home to the work of Dr. Costantino Iadocola's investigations into the link between vascular health and the brain. Another floor has been dedicated to the Division of Immunology and the work of the division chief, Dr. Kendall Smith.

We expect that the opportunities created through the 61st Street Science Building and the planned Medical Research Building on East 69th Street will cause a significant acceleration in the discovery and approval of effective new therapies and improved outcomes.




Weill Cornell Medical College



THE MAGAZINE OF
WEILL CORNELL
MEDICAL COLLEGE AND
WEILL CORNELL
GRADUATE SCHOOL OF
MEDICAL SCIENCES

FALL 2009



Annual Report Issue

FEATURES

22 COMMON CAUSE

BETH SAULNIER

Funded with a \$49 million grant from the NIH, Weill Cornell's Clinical and Translational Science Center aims to bring researchers out of their "silos" to collaborate across disciplines, moving discoveries from bench to bedside and out into the community. A look at the CTSC, including profiles of seven projects it supports—from treating depression among Korean immigrants to diagnosing rejection after kidney transplant.

30 TO SHATTER THE CEILING

SHARON TREGASKIS

Five years ago, the then-president of Harvard sparked a firestorm when he questioned women's innate capabilities in math and science. The fact remains that despite advances toward equality, women still face hurdles ranging from a lack of female mentors to the challenges of juggling work and family. In July, Weill Cornell opened the Office of Faculty Diversity in Medicine and Science, devoted to increasing the number of women in the tenured ranks.

36 WORTH A POUND OF CURE

BETH SAULNIER

Andrew Dannenberg, MD, has devoted his career to studying cancer. He has taken myriad approaches over the past two decades, but they all boil down to one issue: prevention. Today, Dannenberg is sounding the alarm about the relationship between cancer and common conditions like infection and obesity—working to promote therapies and behavioral changes to prevent disease.



Katherine Hajjar, MD, with students

For address changes
and other subscription
inquiries, please e-mail
us at
wcm@med.cornell.edu

DAVID A. COFRIN CENTER FOR BIOMEDICAL INFORMATION

Remembering Weill Cornell alumnus **DAVID A. COFRIN, MD**

The entire Weill Cornell Medical College community mourns the loss of alumnus David A. Cofrin, who died peacefully on August 11, 2009, in Gainesville, Florida, with his wife, Mary Ann, by his side. He was eighty-five years old.



Dr. Cofrin was a “Double Red,” having graduated from Cornell University–Ithaca in 1944 and the Medical College in 1947. Throughout his long and accomplished career as a surgeon in Florida, he remained devoted to his alma mater and to scientific inquiry. His desire to share this lifelong love of medicine and exploration fueled Dr. Cofrin’s philanthropic support of the Medical College and the growth of its academic programs. He was, in fact, Weill Cornell’s most generous alumnus, having given more than \$15 million over the course of six decades.

Dr. Cofrin’s impact on Weill Cornell is indelible. He generously funded the Structural Biology Institute, provided recruitment support for the chair of the Department of Biochemistry, and contributed to the enhancement of the biochemistry labs. He also supported and facilitated ongoing collaborations between his undergraduate and graduate campuses through funding for the Cornell High Energy Synchrotron Source in Ithaca.



His interest in biomedical informatics led to the establishment of the David A. Cofrin Center for Biomedical Information and included support for a unique resource, the Computer Assisted Visualization Environment. The Center has helped to elevate Weill Cornell’s ability to tackle the most challenging questions in systems biology and open the door to major discoveries. For those who recall Dr. Cofrin’s tour of the Center during the spring of 2008, it was evident that his energy and genuine love for the Medical College remained guiding passions well into his retirement.

This dear friend of the Medical College is survived by his wife, brother, children, and grandchildren. The Weill Cornell community is honored to pay tribute to Dr. Cofrin.



DEPARTMENTS

4 DEANS MESSAGES

Comments from Dean Gotto & Dean Hajjar

6 SCOPE

Perelman Heart Institute opens. *Plus:* Campus goes smoke-free, Stewart named clinical affairs dean, burn survivors meet, new student overseer, stimulus funding, WCMC-Q expands pre-med, and remembering Dr. Desiree Pardi.

10 TALK OF THE GOWN

Lepto leap. *Plus:* The “metastatic niche,” practice makes perfect, battling Cooley’s anemia, malaria’s sneaky genes, a big idea, SSRIs and fertility, and mice with Parkinson’s.

40 ANNUAL REPORT

Development report and donor list

48 POST-DOC

A very important date

Weill Cornell Medicine (ISSN 1551-4455) is produced four times a year by Cornell Alumni Magazine, 401 E. State St., Suite 301, Ithaca, NY 14850-4400 for Weill Cornell Medical College and Weill Cornell Graduate School of Medical Sciences. Third-class postage paid at New York, NY, and additional mailing offices. POSTMASTER: Send address changes to Public Affairs, 525 E. 68th St., Box 144, New York, NY 10065.

weillcornellmedicine

THE MAGAZINE OF WEILL CORNELL MEDICAL COLLEGE AND WEILL CORNELL GRADUATE SCHOOL OF MEDICAL SCIENCES

www.weill.cornell.edu

Published by the Office of Public Affairs
Weill Cornell Medical College and Weill Cornell
Graduate School of Medical Sciences

WEILL CORNELL SENIOR ADMINISTRATORS

Antonio M. Gotto Jr., MD, DPhil
The Stephen and Suzanne Weiss Dean,
Weill Cornell Medical College; Provost for
Medical Affairs, Cornell University

David P. Hajjar, PhD
Dean, Weill Cornell Graduate School of
Medical Sciences

Myrna Manners
Vice Provost for Public Affairs

Larry Schafer
Vice Provost for Development

WEILL CORNELL DIRECTOR OF PUBLICATIONS

Michael Sellers

WEILL CORNELL EDITORIAL ASSISTANT

Andria Lam

Weill Cornell Medicine is produced by the staff
of *Cornell Alumni Magazine*.

PUBLISHER

Jim Roberts

EDITOR

Beth Saulnier

CONTRIBUTING EDITORS

Adele Robinette
Sharon Tregaskis

EDITORIAL ASSISTANT

Tanis Furst

ART DIRECTOR

Stefanie Green

ASSISTANT ART DIRECTOR

Lisa Banlaki Frank

ACCOUNTING MANAGER

Barbara Bennett

EDITORIAL AND BUSINESS OFFICES

401 E. State St., Suite 301
Ithaca, NY 14850
(607) 272-8530; FAX (607) 272-8532



Weill Cornell Medical College

Printed by The Lane Press, South Burlington, VT.
Copyright © 2009. Rights for republication of
all matter are reserved. Printed in U.S.A.

Help Wanted

**Antonio M. Gotto Jr.,
MD, DPhil, Dean of the
Medical College**



JOHN ABBOTT

The practice of medicine is much more than a career. It is a calling—a lifelong effort to unravel the secrets of the human body. To heed that calling is to invite a life of great sacrifice and endless work. It is not easy, and it is not for everyone.

By that standard, it should come as no surprise that the need for physicians in New York State greatly exceeds the supply—and the gap is growing. According to a recent report released by the State University at Albany’s Center for Health Workforce Studies, by 2030 there will be

a shortfall of 2,500 to 17,000 physicians.

The report, “New York Physician Supply and Demand Through 2030,” finds that the greatest gaps are expected to occur in New York City and the Hudson Valley, where demand is projected to grow most rapidly. While no region will be immune, physician-supply growth should more closely parallel demand growth in the Capital District and Finger Lakes regions, while Western New York is expected to experience a decline.

New York City will have the greatest growth in demand. And while the number of physicians in the city is expected to increase overall, several specialties are projected to show declines, including ophthalmology, pathology, psychiatry, urology, and surgical disciplines. The numbers of practitioners in general internal medicine, family medicine, obstetrics and gynecology, and otolaryngology are expected to grow for a period, but then decline after 2020. Other areas are expected to show growth through 2030, including anesthesiology, cardiovascular disease, emergency medicine, general pediatrics, orthopaedic surgery, and radiology.

Each year, about 5,000 of the brightest and most accomplished undergraduates apply to Weill Cornell. They represent some of the best universities in the United States and abroad, and boast GPAs and MCAT scores that are all but unbeatable. The vast majority of them are seeking medical degrees, while others are prospective PhD students or candidates for our MD-PhD program. Only about 100 of these young men and women will be admitted, and by the time their clinical education, residencies, internships, fellowships, and other activities have concluded, many of them will have left New York City.

But because the city is a unique place to live and work—and also because of the facilities, partnerships, and professional opportunities that Weill Cornell and NewYork-Presbyterian Hospital can offer—many of those students-turned-physicians do stay in the city that never sleeps. They can practice anywhere in the world, but our graduates know only too well how much they are needed here. Many of our longest-serving and most prestigious faculty members began their medical careers on the Upper East Side—a trend that we hope to see continue and grow stronger. More than ever, it appears, we will need them here.

Star Search

David P. Hajjar, PhD,
Dean of the Graduate
School of Medical Sciences


It is no secret that we live in a society obsessed with fame and celebrity. Even in the world of science, the yearning for fame—and maybe worldwide recognition for a major research discovery—is prevalent. But whenever someone mentions the concept of a “superstar” researcher, I can’t help but laugh.

The scientists, technicians, and assistants who populate the laboratories of Weill Cornell Graduate School of Medical Sciences are brilliant, accomplished men and women advancing the scope of knowledge in their chosen fields. I don’t get the impression that they are daydreaming about stardom. It is the pursuit of knowledge and understanding that drives them, not the pursuit of some individual award or recognition.

But that’s not to say that our faculty and students aren’t among national—even world—leaders when it comes to research achievements and funding. For example, Jonathan Bourne—a physiology, biophysics, and systems biology student in Dr. Peter Torzilli’s lab—was awarded second place in the PhD student paper competition and poster presentation at the 2009 Summer Bioengineering Conference in Lake Tahoe, California. He placed in the Tissue and Cellular Biomechanics and Imaging category for his presentation, “Collagen Molecular Conformation Exhibits Strain-Rate Dependent Response to Axial Deformation in Silico.” Jonathan’s research was supported through an NIAMS grant and the NIH-supported Clinical and Translational Education Program of Weill Cornell’s Clinical and Translational Science Center, recently established with the help of a \$49 million NIH grant.

As you know, grant funding is the lifeblood of research at an academic medical center. Not only does it make our work possible, but support from the NIH and other entities raises the profile of an institution, attracting key personnel and helping to secure needed equipment and infrastructure. It’s an open secret that some academic institutions use their funding to promote research “superstars,” hoping to bolster their reputations based on a personality rather than the collective intellects of faculty, graduate students, lab assistants, and staff.

Thanks to the American Recovery and Reinvestment Act of 2009 (a.k.a. President Obama’s “Stimulus Package”), Weill Cornell Medical College recently secured millions of dol-



ABBOTT

lars in new research funding. Much of that money will support scientists in the Graduate School. In fact, as of late September, we have received dozens of stimulus grants to bolster existing programs and launch new ones. We are fortunate to have the full support of our Board of Overseers and the institution’s administration, and the mutual respect and confidence of those who provide the funds that support our important work. We have talented people who sincerely believe they can make the world a better place with regard to patient care.

After the Summer Bioengineering Conference, Jonathan Bourne said, “I’m grateful that my work was recognized, but—more important—this award acknowledges the training and mentoring available to us and the relevance of research done at Weill Cornell to the scientific community.”

Substance rather than celebrity—I could not have said it better myself.

Peter Torzilli, PhD, and doctoral candidate Jonathan Bourne

Scope

News Briefs

Patient-Focused Heart Institute Opens

Preventing heart disease in women will be a priority of new Ronald O. Perelman Heart Institute



RICHARD LOBEL

Heart felt: On hand to mark the opening of the Perelman Heart Institute were (from left) David Letterman, Mayor Michael Bloomberg, Ronald Perelman, NYPH CEO Herbert Pardes, MD, NYPH trustee David Koch, and Institute head O. Wayne Isom, MD.

In September, NewYork-Presbyterian Hospital/Weill Cornell Medical Center celebrated the opening of the Ronald O. Perelman Heart Institute in a ceremony where dignitaries included New York City Mayor Michael Bloomberg and TV host (and former cardiac patient) David Letterman. The facility—made possible by a \$25 million gift from Perelman, a NYPH trustee—will offer comprehensive cardiovascular care and heart-health education. The physical plant includes a new five-story atrium designed to be a “medical town square” featuring a patient welcome center, clinical trials enrollment center, and education resource center. This new facility, said NYPH President and CEO Herbert Pardes, MD, allows the hospital “to build on an already strong foundation, establishing new standards of quality care and a new concept of what is possible for patients and their families.”

Among the institute’s priorities: bridging the gender gap in cardiovascular medicine. Although women are twice as likely as men to die after a heart attack, heart disease was long considered a man’s issue—making women less likely to identify symptoms or seek treatment. “Clearly, we are making a statement to our patients about our commitment to cardiac care, with a special emphasis on heart health and women,” said Dean Antonio Gotto. “Mr. Perelman’s gift will save many lives.”

Stewart Named Senior Associate Dean for Clinical Affairs

Effective January 1, Michael Stewart, MD, will become senior associate dean for clinical affairs. He succeeds retiree E. Darracott Vaughan, MD, now chairman emeritus of the Department of Urology. In his new role, Stewart will oversee matters involving clinical organization and patient care, serving as the chief liaison between clinical faculty, the Physician Organization, and the dean's office. Stewart will remain chairman of otorhinolaryngology at Weill Cornell and otorhinolaryngologist-in-chief at NYPH/WCMC.



WEILL CORNELL ART & PHOTOGRAPHY

Michael Stewart, MD

Medical College Goes Smoke-Free

In August, Weill Cornell joined forces with NYPH and Hospital for Special Surgery to create a completely smoke-free campus. Smoking is now prohibited virtually everywhere on college grounds, including building entrances, courtyards, garages, plazas, and sidewalks. The new "Smoke-Free WCMC" policy has been added to employee and student handbooks, and the Medical College is offering free smoking-cessation workshops and other services for people who want to kick the habit.

Burn Center Sponsors Survivor Event

In August, hundreds of burn survivors and their families attended a conference at the Sheraton Hotel in Midtown, sponsored by Weill Cornell's Hearst Burn Center and the New York Firefighters Burn Center Foundation. The event included workshops on such topics as how to use cosmetics to conceal burns and how burn injuries can impact families. Guest speakers included Roger Yurt, MD, director of the Burn Center, which is the busiest in the nation. Kim Phuc Phan Thai, the subject of a famous photograph taken during the Vietnam War that showed her running down the street crying after suffering burns from a napalm attack, spoke about living with a severe burn injury. The event was hosted by the Phoenix Society, the largest national nonprofit serving burn survivors.

MD-PhD Student Elected to Board of Overseers

Weill Cornell students have elected MD-PhD candidate Jeffrey Russ to a three-year term as student representative on the Board of Overseers. He will attend the board's four annual meetings, serving as the voice of medical and graduate students. Russ, who helped found the Student Green Initiative at the Medical College, ran on a platform of environmental and sustainability issues. "I thought this would be a good way to implement some of the projects that I've been working on with people who can really make changes," he says. A graduate of the University of Pennsylvania, Russ previously served on the Medical Student Executive Committee.

WCMC-Q Expands Options for Pre-Meds

Starting with the class that matriculates next August, the Qatar branch is adding a third year to its pre-med program. "The three-year pre-medical curriculum will provide greater course breadth, more opportunities for research and independent study, more time to acquire English language skills, and greater opportunity for academic success," says Interim Dean Javaid Sheikh, MD. All students will take the same classes during the first semester; then, based on their grades, some will have the option to finish in two years on an accelerated track.

Grant Establishes Disparities Research Center

Associate professor of medicine and public health Carla Boutin-Foster, MD, MS '99, has been awarded a five-year, \$8 million grant from a division of the NIH to support a Comprehensive Center of Excellence in Disparities Research and Community Engagement. The aim of the center—a consortium that includes Weill Cornell, Hunter College, CUNY, and NYU—is to integrate research with community outreach in an effort to improve minority health. Its funding comes from the National Center on Minority Health and Health Disparities; Boutin-Foster will serve as director.

Picture this: A portrait of the Medical College's foremost benefactor, Sanford Weill, and Dean Antonio Gotto was presented at a small ceremony in September. In attendance were (from left) Dean Gotto and his wife, Anita Gotto, and Joan and Sanford Weill. The portrait, by Everett Raymond Kinstler, hangs in the lobby of the Weill Greenberg Building.

RICHARD LOBEL





WEILL CORNELL ART & PHOTOGRAPHY

Desiree Pardi, MD, PhD

Remembering Dr. Pardi

Assistant professor of medicine Desiree Pardi, MD, PhD, director of the Palliative Care Consult Service at NYPH/WCMC, died in September after a battle with breast cancer. A 2002 graduate of Mount Sinai School of Medicine, Pardi did her residency in internal medicine at NYPH/WCMC and a fellowship in pain management at Sloan-Kettering. She was board certified in internal medicine and hospice and palliative medicine.

Mark Lachs, MD, co-chief of the Division of Geriatrics and Gerontology, notes that Pardi was one of the founders of the consult service at NYPH/WCMC and a “tireless advocate” for the cause of palliative care. “She was generous of her time and expertise to teach the art and science of palliative care to all levels of learners,” Lachs says. “She had a profound impact not only on the thousands of patients whose lives she touched, but played a significant role in transforming the culture of the institution around the issue of palliative care.”

The Desiree Pardi, MD, Memorial Fund for Palliative Care has been established; according to Lachs, plans are also in the works to name a family room at the hospital in her honor.

“Dr. Pardi was an inspiration to all of us, enriching our lives and making us all better for having had the privilege and joy of working with

her,” said three colleagues in a statement announcing her death. “She was beloved by the medical students whose lives she touched in her many teaching activities.”

WCMC Garners Federal Stimulus Funds

As of mid-October, Weill Cornell researchers had received more than five dozen NIH grants under the American Recovery and Reinvestment Act of 2009. The stimulus funding includes work in such fields as AIDS, kidney disease, cancer, Parkinson’s disease, and more. The single largest grant—\$1.9 million from the National Institute on Drug Abuse—went to Ronald Crystal, MD, the Bruce Webster Professor of Internal Medicine, to develop an adenovirus-based anti-cocaine vaccine.

Correction

Due to an editorial oversight, the name of Margaret Bearn, wife of fifty-six years to Dr. Alexander Bearn, was omitted from his obituary in the Summer 2009 issue. In addition to his wife, Dr. Bearn is survived by his two children, five grandchildren, and brother. We sincerely regret the error.

TIP OF THE CAP TO...

J. Emilio Carrillo, MD, associate professor of clinical public health, winner of the National Medical Fellowships Distinguished Alumni Award.

Joseph Fins, MD ‘86, chief of the Division of Medical Ethics, elected to the American Osler Society, which comprises members of the medical profession and allied fields who follow the example of William Osler, MD, a father of modern medicine.

Heather Taffet Gold, PhD, assistant professor of public health, who won the award for best paper by a young investigator from the Society of Medical Decision Making for “Correlates and Effect of Suboptimal Radiotherapy in Women with

Ductal Carcinoma in Situ or Early Invasive Breast Cancer.”

Tobias Hohl, PhD ‘00, MD ‘01, an assistant professor in the Division of Allergy and Infectious Diseases at the University of Washington, Seattle, winner of the Young Investigator Award from the American Society for Microbiology.

Yoon-Seong Kim, MD, PhD ‘03, assistant professor of neuroscience, one of ten winners of grants from the Michael J. Fox Foundation to study Parkinson’s disease.

David Lyden, MD, PhD, the Stavros S. Niarchos Associate Professor in Pediatric Cardiology, named head of the Champalimaud

Metastasis Programme at Weill Cornell.

Michael Posner, PhD, adjunct professor of psychology in psychiatry, awarded the National Medal of Science by President Barack Obama.

Marcus Reidenberg, MD, professor of pharmacology, elected chair of the WHO’s Expert Committee on the Selection and Use of Essential Medicines.

Cornell President **David Skorton, MD**, named by U.S. Health and Human Services Secretary Kathleen Sebelius to a four-year term on the advisory council of the National Institute of Biomedical Imaging and Bioengineering.

FROM THE BENCH

Genetic Test Could Aid Colon Cancer Treatment

Some 29,000 people in the U.S. have metastatic colorectal cancer. Of those, one in ten have a variant in their DNA that causes white blood cell counts to drop after they undergo standard chemotherapy, putting them at higher risk for bacterial infections and even death. To prevent this, a new genetic test has been developed to identify high-risk patients, potentially allowing physicians to put susceptible patients on lower doses; researchers have now evaluated its cost effectiveness. In work published in *Cancer*, they determined that testing can be beneficial—but only if reduced doses are as effective as full doses. The work, says lead author Heather Taffet Gold, PhD, assistant professor in the Division of Health Policy, “remains to be verified by clinical research.”

Quick Response Is Key in Bioterror Attacks

In the event of an anthrax attack on a major metropolitan area, rapid response and treatment are vital, says associate professor of public health Nathaniel Hupert, MD. In work published in *Medical Decision Making*, Hupert and colleagues report that any delay beyond three days in distributing antibiotics would overwhelm hospitals with critically ill patients. “No matter how well-organized and prolonged a treatment program is, it must be quickly implemented,” Hupert says. “In fact, our analysis shows that time-to-treatment is roughly twice as important as the duration of the distribution program.”

Targeted Prostate Therapy

Researchers have discovered a new gene fusion that is highly expressed in 5 percent of prostate cancers. The fusion, known as NDRG1-ERG, produces a cancer-specific protein that may serve as a target for drug therapies. According to Mark Rubin, MD, the Homer T. Hirst Professor of Oncology in Pathology, the discovery “may help physicians prescribe tailored therapies for their patients by avoiding the trial and error that is often associated with cancer treatments.” The work, which was published in *Neoplasia*, could also make it easier to distinguish between cancer and non-lethal diseases such as benign prostatic hyperplasia.

ECG May Predict Cardiac Death

A measure of the time it takes for an electrical signal to travel through a pumping heart—known as QRS duration, or QRSd—could help physicians identify patients at risk for sudden cardiac death. Using data drawn from the LIFE study (a large, multicenter hypertension study lasting seven years and comprising more than 9,000 patients), cardiologist Peter Okin, MD '80, and colleagues found a clear link between prolonged QRSd and

sudden cardiac death. “No one has ever really looked at this,” Okin says, adding that further studies on larger patient populations will be needed to ascertain if QRSd is a cause of death or merely an indicator. The research was published in the *European Heart Journal*.

Why Are African Americans Predisposed to Kidney Disease?

African Americans comprise 32 percent of all patients treated for kidney failure and are four times more likely than whites to develop renal disease; a new study may help explain why. Manikkam Suthanthiran, MD, the Stanton Griffis Distinguished Professor of Medicine, and Phyllis August, MD, the Ralph A. Baer Professor of Medical Research, have found that blacks are more likely to have elevated levels of the protein TGF-beta1, which raises the risk of hypertension and kidney disease. Although the mechanisms of TGF-beta1 require further study, the authors say that it may boost retention of sodium in the kidneys and also may affect the activity of renin, an enzyme that constricts blood vessels and raises pressure. The results were published in *Kidney International*.

Preventing Suicide and Depression in Older Adults

“Almost one in ten older adults in the United States has some form of depression,” states George Alexopoulos, MD, “and one-fifth among them contemplates suicide.” Director of the Institute of Geriatric Psychiatry at the Westchester Division, Alexopoulos is lead author of a two-year study of suicide prevention in older adults that followed some 600 patients. He points out that although most older adults are seen by primary care physicians, depression often goes untreated because of doctors’ time constraints and patients’ reticence to discuss their symptoms. The results were published in the *American Journal of Psychiatry*.

A New Front in the TB Battle

Researchers have identified compounds that inhibit the ability of tuberculosis-causing bacteria to survive dormant in infected cells—a key reason why the disease is so hard to combat. The work, published in *Nature*, could lead to more powerful TB treatments. “There are few drugs that successfully combat TB in its dormant stage, which makes the bacterium so resilient in the body,” says senior author Carl Nathan, MD, the R. A. Rees Pritchett Professor of Microbiology, whose team screened 20,000 compounds for TB inhibition activity. “More important, there are many antibiotics that kill bacteria by blocking the synthesis of proteins, but there are none that kill bacteria by interfering with protein breakdown, as we have found here.” Worldwide, *Mycobacterium tuberculosis* infects one person in three.



JOHN ABBOTT

Nathaniel Hupert, MD



WEILL CORNELL ART & PHOTOGRAPHY

Peter Okin, MD '80

Talk of the Gown

Insights & Viewpoints



PROVIDED

Urban Illness

A Brazil-based researcher develops a rapid test for leptospirosis, a scourge of slums in the developing world

Infectious agent: *Leptospira interrogans* bacteria

A disease that causes untold suffering in many desperately poor urban slums is closer to being conquered, thanks to a collaboration among Weill Cornell researchers, Brazilian scientists, and a U.S. biotech company. Little known in the developed world, leptospirosis is endemic in the slums of Rio de Janeiro, Mumbai, Cali, Jakarta, Manila, and other impoverished areas. Infection occurs when people are exposed to urine from rats, cattle, pigs, horses, dogs, and other animals whose kidneys have been colonized by *Leptospira* bacteria; when tropical storms or hurricanes cause open sewers to overflow, people can come into contact with contaminated water or soil.

Because the early symptoms of leptospirosis can resemble illnesses such as flu, malaria, or dengue fever, a definitive initial diagnosis is often difficult. Early treatment is critical, though: illness can quickly progress from the initial stage of fever, chills, and vomiting to the more severe Weil's disease, which can lead to meningitis or failure of the liver or kidneys. Weil's disease has a 10 to 15 percent fatality rate, but an even more dangerous form—severe pulmonary hemorrhage syndrome, in which half of patients die—has emerged in the Brazilian shantytowns, or *favelas*. Each year, there are an estimated 500,000 new cases of leptospirosis worldwide; in Brazil, more than 12,000 people contract the more severe forms of the disease.

Last year, a group of infectious disease scientists led by Albert Ko, MD, an associate professor in Weill Cornell's Division of Infectious Disease who is based in Brazil, developed a successful prototype test for leptospirosis—one that requires only a finger-prick blood test and yields a highly accurate result within fifteen minutes. Because the diagnostic test currently in use is woefully inadequate, a way to establish early infection has been the holy grail. "To make a definitive diagnosis using the current test requires two blood samples, one during the acute illness phase and another three weeks later," says Ko. "But in the *favelas*, where families live on about \$2 a day, the patient may not even have the fare to travel back to a clinic for the second test and many die before returning." Even if two samples are obtained, it can take months or even a year to get a diagnosis, because only a few labs



PROVIDED

Field work: An urban slum study site. Bottom: Infectious disease professor Albert Ko, MD (in white shirt on far right), with his research team.

in the world do the testing. Without fast and appropriate treatment, the patient may develop profound health problems—particularly devastating because the disease most often strikes adult breadwinners.

More than forty years ago, under the leadership of Warren Johnson, MD, now director of Weill Cornell's Center for Global Health, the Medical College launched a program to study tropical diseases in Brazil. Since then, urbanization has transformed the country: about 90 percent of Brazilians live in cities and of those, 30 to 40 percent live in *favelas*. Ko came to Brazil as an infectious disease fellow in 1996 and never left; in 1999, the *Lancet* published his early leptospirosis work, which drew attention to the fact that it was changing from a mostly rural phenomenon—striking farmers in China, for example—to one affecting poor city dwellers.

For the 2008 study,

Ko collaborated with Konstantin Lyashchenko, PhD, senior R&D director at ChemBio, a New York-based company that specializes in rapid diagnostics, and a team headed by Mitermayer Reis, MD, PhD, at the research branch of the Brazilian Ministry of Health. They discovered how to create biological markers for leptospirosis from antibodies of infected patients; ChemBio created the prototype using a proprietary method that allows heightened sensitivity to protein markers. These Phase I studies showed an 85 percent overall sensitivity rate to the markers and a 78 percent success rate in identifying leptospirosis in the first seven days of illness—the crucial window during which antibiotics provide the greatest benefit.

In Phase II—funded by a \$3 million NIH Small Business Innovative Research grant—the team is working to fully develop the rapid test and bring it to market. "Although leptospirosis is a major health problem in many poor countries, it also is an emerging issue in developed countries," says Ko. "As the climate changes and causes more flooding, microbes such as the pathogen that causes leptospirosis will flourish. Coupled with the fact that by 2025 an estimated two billion people will live in cities, infectious diseases like this are going to become better known in many more parts of the world."

— Anna Sobkowski



PROVIDED

Soil & Seed

Oncologist David Lyden explores
the mechanism of metastasis

In the garden, an abundant harvest relies equally on quality seed and healthy soil. The same principle applies to the metastasis of cancer—without a welcoming niche in distant organs, a primary tumor may grow, but it won't spread. The concept isn't new; in 1889, a young West London physician investigated more than 700 cases of fatal breast cancer, deploying an agricultural metaphor. "When a plant goes to seed, its seeds are carried in all directions," Stephen Paget mused in a paper published in the *Lancet*. "But they can only live and grow if they fall on congenial soil." The metaphor seems intuitive—yet for nearly a century, Paget's hypothesis was largely ignored.


Though prevailing theories of the time credited the circulatory system with distribution of cancerous cells, Paget found that the liver disproportionately hosted secondary lesions—while the spleen, equally exposed to cancer cells in the

blood, did not. Metastasis, he concluded, must owe to more than chance. "The best work in the pathology of cancer is now done by those who . . . are studying the nature of the seed," he wrote. "They are like scientific botanists; and he who turns over the records of cases of cancer is only a ploughman, but his observation of the properties of the soil may also be useful."

Since the late Nineties, Weill Cornell pediatric oncologist David Lyden, MD, PhD, has bent his shoulder to the work Paget described, detailing the biochemical mechanisms that prepare the "soil" for metastatic cancer. In the intervening decade, *Nature*, *Science*, and a dozen other journals have published Lyden's step-by-step analysis of the process that transforms healthy cells into tumor emissaries, preparing what he calls the "pre-metastatic niche." "Paget came up with the original theory, but he didn't have the tools to investigate it," says Lyden, the

David Lyden, MD, PhD

JOHN ABBOTT



Stavros S. Niarchos Associate Professor in Pediatric Cardiology. “We were lucky to have the tools—molecular biology, microarrays, characterization of the proteins on the surface of the cells, the known enzymes that participate.”

Lyden has high hopes that today’s analytic tools and the insights they reveal will transform the prognosis for patients with advanced cancer. Ninety percent of cancer fatalities owe to metastasis, says Lyden—yet oncologists don’t know enough about the process in humans to short-circuit it. “Even though standard treatment of surgery and chemotherapy has improved survival, there are too many deaths and too many side effects,” says Lyden, who treats children with brain tumors at Memorial Sloan-Kettering Cancer Center. “We need selective therapies and targets.” Chemotherapy works by killing any rapidly dividing cell, he notes, from cancer to hair to the lining of the digestive tract. That means there’s a lot of collateral damage associated with current treatment options. “The better approach is to understand all of the steps in metastatic disease,” he says. “If we understand what’s going on in metastatic tissue, and if it’s specific to metastatic tissue, then we should target that rather than anything that’s a dividing cell.”

Already, Lyden and his collaborators have documented the role of growth factors secreted by the tumor in preparing the way for metastasis, described how stem cells in bone marrow establish the vascular supply for distant lesions, and detailed the influence of inflammation on the pre-metastatic niche using mouse models. In April 2009, *Nature Reviews Cancer* published “The Metastatic Niche: Adapting the Foreign Soil” by Lyden and Bethan Psaila, a research associate in the Department of Hematology at London’s Imperial College School of Medicine, who completed a Fulbright fellowship in his lab. “There’s a balance of the cancer and the host,” says Psaila. “Targeting the cancer cells alone isn’t enough. You also need to target the normal cells, the normal microenvironment, because they play a role. It’s obvious that you need to design treatments that attack cancer cells, but it’s less obvious that the body is playing a role as well.”

Perhaps, the researchers say, the team’s most important insight boils down to a matter of timing. “The tumor cells are released early on, circulating even when you have a small, localized tumor,” says Rosandra Kaplan, Weill Cornell’s Charles,


Lillian, and Betty Neuwirth Clinical Scholar in Pediatric Oncology and an assistant professor of pediatrics who did a fellowship in Lyden’s lab and continues to collaborate with him. “The circulating cells make a welcoming committee. They’re changing the landscape and changing the microenvironment.” In

their current work using human tissue samples, Lyden and Kaplan have focused on further exploring the biochemical processes under way at prospective metastatic sites at the earliest stages of a primary tumor’s development. Says Kaplan: “David challenges people to think differently.”

— Sharon Tregaskis

In Practice

Studying physicians on the front lines



Lawrence Casalino, MD, PhD

JOHN ABBOTT

As debate rages over health-care reform, many opponents of the Obama Administration’s plan have repeated a common refrain: a system of national health care “will put a bureaucrat between you and your doctor.” Regardless of where one stands on the proposals currently battling their way through Congress, a study by Weill Cornell researchers has found that one thing’s for sure: there’s plenty of red tape already—though not necessarily from government bureaucrats.

In a national survey of physician practices, Lawrence Casalino, MD, PhD, and colleagues reported that, on average, doctors spend the equivalent of nearly three work weeks a year on administrative tasks required by private health insurance companies—and the figure is even higher (more than four weeks) for primary care physicians in small practices. The study, whose results were published in *Health Affairs* in May, also found that nurses spend more than twenty-three weeks per physician per year on such tasks—which include prior authorization, pharmaceutical formularies, claims, billing, and

credentialing—and clerical staff forty-four weeks.

When time is converted to dollars, the annual bill equals \$23 billion to \$31 billion—and, Casalino adds, when factors such as the costs of computer equipment and office space are included, the figure is more like \$41 billion. “It’s not just a question of the dollars,” he says. “I can tell you, having been in private practice for twenty years, that it’s demoralizing to physicians and their staffs to have their days continually interrupted by tasks that seem, at best, irrational.”

The response rate for the survey was 58 percent, and the researchers received 895 completed surveys from physicians and medical group administrators. On average, the MDs reported spending the equivalent of about \$68,000 worth of their time per year interacting with health plans—nearly a third of the salary, plus benefits, for a typical primary care physician. “Sixty-eight thousand dollars per physician is disturbing,” says Casalino, chief of the Division of Outcomes and Effectiveness Research in the Department of Public Health. “For a primary care physician in a small practice, over four weeks a year is spent dealing with health plans. A physician can see a lot of patients in four weeks.”

But Casalino stresses that not every interaction with a health plan should be deemed wasteful. “Some of that \$41 billion is probably money well spent,” he says. “For instance, if requiring certain physicians to get prior authorization before their patients have an MRI scan means that a lot of inappropriate MRIs are avoided, then you can’t say that all the time spent on prior authorizations is wasted.” Casalino and his collaborators are currently conducting a similar study on physician practices in Canada.

The surveys on health plan interactions are just one facet of Casalino’s studies on physician practices; in other recent work, published in the *Archives of Internal Medicine* in June, he and colleagues examined how often practices fail to inform patients of abnormal test results. They focused on eleven types of blood tests as well as three common screenings: mammography, Pap smear, and fecal occult blood. In analyzing some 5,400 records from twenty-three practices, they found that, on average, patients aren’t informed of abnormal results once out of every fourteen cases. At some practices, the rate was zero; at others, it was as high as one in four.

One of the most common reasons for a lapse in reporting results, he says, is the practice of telling patients to assume that “no news is good news.” He was motivated to undertake the study after it happened in his own household: his wife had gone for a routine Pap smear, and when the nurse practitioner looked at her record, he says, she “went white.” The previous year, Casalino explains, his wife had had a uterine ultrasound, but the troubling results—which might have indicated endometrial cancer—had never been reported to her. “After all the stories she had heard from me over the years, my own wife assumed no news was good news,” Casalino says. “These mistakes are widespread.” (Luckily, she proved to be cancer-free.)

Having served as a family physician in a nine-doctor group practice in California from 1980 to 2000, Casalino is devoted to improving medicine by focusing on its front lines. Physicians, he says, are the “final common pathway” for health care. “Not to say that nurses and other staff are not important,” he

says, “but things don’t happen unless physicians order them. The cost and quality of health care depend heavily on what physicians do. Understanding more about how physicians practice is fundamental to understanding medical care in the U.S.” Alvin Mushlin, MD, ScM, chairman of the Department of Public Health, confirms the importance of Casalino’s work and says, “We were delighted to have Larry Casalino join our department to lead this area of research in order to provide insights that can improve the delivery of medical care.”

Casalino admits that studying physician practices is logistically challenging. “It’s devilishly hard to get data,” he says, because unlike hospitals or health plans, there’s no national census of medical practices. “When we started doing this in the early Nineties, not many people were studying them, for that reason: no one knows who they are or what physicians are in them.” Now, he says, “more people are getting into the field of studying physician practices—but it still isn’t studied as much as it ought to be in relation to its importance.”

— Beth Saulnier

Blood Ready

Getting closer to a cure for an ‘orphan’ disease

After sickle-cell anemia, beta-thalassemia major—known as Cooley’s anemia—is the world’s most common inherited disease. The World Health Organization estimates that between 50,000 and 100,000 children are born with it each year; an estimated 60 million to 80 million people carry the beta-thalassemia trait, which is especially prevalent in Mediterranean countries, North Africa, and Asia. In the U.S., the number of Cooley’s patients is estimated to be between 1,000 and 1,500. While it is a small population, they’re among the largest consumers of red blood cells in the nation. A 2007 study in the *American Journal of Hematology* estimates that Cooley’s anemia can cost as much as \$75,000 per patient per year in the U.S. Weill Cornell treats 100 to 200 Cooley’s

patients annually.

Stefano Rivella, as a PhD student of genetics at Italy’s University of Pavia, worked on the Human Genome Project and human genetic disorders. Later, as a postdoc at Memorial Sloan-Kettering Cancer Center, he focused on beta-thalassemia, using mouse models to study the disorder. At Weill Cornell, Rivella and his collaborators have further characterized these mouse models that have mutations in the beta globulin gene responsible for the mutations in red blood cells that cause Cooley’s anemia. The finding, published in the journal *Blood* in 2008, is one step toward a cure; preclinical trials show promise for new therapies for patients with splenomegaly (an enlarged spleen), a frequent symptom.

One of the obstacles to research on Cooley’s anemia is its status as a so-called “orphan” disease. Although the Centers for

Disease Control and Prevention funds seven Cooley's centers in the U.S., including one at Weill Cornell, the fact that there are relatively few patients in North America means the illness gets little attention here. Studies are rare and under-funded, and current management of the disease is limited to pre-natal diagnosis, transfusion therapy, iron chelation, and bone marrow transplants. While this has led to greater life expectancy for Cooley's patients in developed countries—upwards of forty years—the disease is near epidemic levels in such places as the Maldives, Iran, North Africa, and Southeast Asia, where infants born with it face an early death.

The situation may be even graver: worldwide mortality rates are often under-

globin, a protein in red blood cells that carries oxygen. All thalassemias are recessive and inherited from both mother and father, but not all are life-threatening. Severity depends on the mutations and their interplay, with Cooley's being the worst. Patients commonly experience extreme fatigue, shortness of breath, and splenomegaly, caused by a buildup of crippled or dead red blood cells as well as from the frequent transfusions—generally twice a month—needed to sustain life. “The spleen acts like a filter and a sponge, cleansing the blood,” says Rivella, associate professor of genetic medicine in pediatrics. “In people with Cooley's anemia, it is overworked and becomes saturated. Because so much



PROVIDED BY STEFANO RIVELLA

Down to size: Mouse spleens illustrate the reducing effects of a promising drug for Cooley's anemia patients.



Stefano Rivella, PhD

JOHN ABBOTT

estimated, as Cooley's symptoms mimic those of malaria. Even in the U.S., Cooley's is sometimes mistaken for sickle-cell anemia, a disease that disproportionately affects African Americans. Curiously, both sickle cell and thalassemia are believed to be evolutionary adaptations to the presence of malaria in tropical climates, offering some degree of protection from the blood-borne disease.

Thalassemias are genetic disorders marked by the absence of (or defects in) the genes responsible for production of hemo-

blood is sequestered in the spleen, we have to give the patient even more. This comes with a cost.”

That cost is a toxic buildup of iron that must be removed by chelation therapy to prevent heart and liver disease, among other problems. The common alternative, surgical removal of the spleen, leaves patients vulnerable to disease and stroke and dependent on a battery of anticoagulants, vaccinations, antibiotics, and auto-immune boosters in addition to transfusions and chelation.

Despite the downsides, splenectomy is a common life-saving treatment for thalassemia patients.

But there may be a way to avoid it. Research on mouse genes and cells has led to a better understanding of the processes of Cooley's anemia, particularly the activity of a gene called JAK2, which plays a major role in the formation of aberrant red blood cells in beta-thalassemia. A new compound developed for clinical trials on patients with myelodysplastic disorders (MDPs), another group of blood diseases, appears to work wonders on mice with beta-thalassemia by blocking expression of JAK2. “We found that this JAK2 inhibitor caused the spleens in the mice to shrink back to normal size,” Rivella says. “They also began to produce better red blood cells.”

Rivella says the compound could become part of a cure for Cooley's anemia—but so far it has been cleared in the U.S. only for trials on MDPs. He hopes his initial

research will not only improve treatment for Cooley's patients but also convince drug companies—and perhaps a sponsor—to support clinical trials. “Based on our observations, it is clear that this JAK2 inhibitor has a positive influence on the disease, and it is a matter of gathering perhaps \$200,000 for trials on five or six patients,” says Rivella. “That's not a lot when you think about the cost of clinical trials. The drug is available. We don't have to invent it. We just need some help to get started.”

— Franklin Crawford

Sticky Problem

Exploring the mysteries of the malaria parasite



Kirk Deitsch, PhD

Each year, 350 million to 500 million people are infected with malaria and more than a million die from it—most of them African children under five. “It’s a devastating disease,” says Kirk Deitsch, PhD, associate professor of microbiology and immunology, “and to fight it we need a better understanding of the basic molecular and cellular biology of malaria parasites and how they interact with their human and insect hosts.”

Deitsch has devoted his career to studying how *Plasmodium falciparum*—the protozoan parasite that causes most severe malaria infections—dodges the human immune response. In collaboration with colleagues in pharmacology and microbiology, he also investigates mechanisms of drug resistance and works to develop new antimalarials.

The *P. falciparum* parasites are transmitted to humans via the bite of an infected mosquito. After they first multiply in the liver, the parasites invade and destroy red blood cells, causing symptoms such as anemia and fever. The parasite places a protein called PfEMP1 on the surface of the infected red cells so they become cytoadherent (or “sticky”) and cling to the walls of blood vessels; this prevents the bloodstream from carrying the infected cells to the spleen, where they’d be filtered out.

With time, the immune system begins producing antibodies against the protein and destroying the parasites—but a small number of them change the sticky protein they’re placing on the surface of infected cells. This process, known as antigenic vari-

ation, lets them avoid the immune response and maintain infection. "Over the length of an infection, you'll see waves in which parasites are getting wiped out and then new populations are arising that express a different protein on the surface," says Deitsch, winner of a 2002 Presidential Early Career Award in Science and Engineering.

The parasite owes its ability to outsmart the immune system to a family of genes called *var*. Within its genome, each parasite contains up to sixty *var* genes. Only one is expressed at a time, determining which protein is displayed on the surface of the infected red blood cell. Deitsch's research focuses on how the parasite coordinates that expression. "It's one of the most fascinating puzzles in all of genetics," he says.

After completing his doctorate in genetics at Michigan State in 1994, Deitsch spent five years as a postdoc under Thomas Wellem, MD, PhD, in the Laboratory of Parasitic Diseases at the National Institutes of Health. Wellem and his team had recently discovered *var* genes, and his work with Deitsch resulted in the discovery of the two primary DNA elements that control their regulation. In a paper published in *Nature* in 2001, they described how one of the elements sits upstream of each gene along the chromosome and the other sits in the intron (or non-coding section) of each gene; they work together to silence expression of all but one *var* gene at a time. Since joining the Weill Cornell faculty in 2001, Deitsch has continued to explore how those elements interact.

Deitsch and his team have created transgenic parasites that have several *var* genes "on" at one time, as well as parasites with *var* genes that do not encode for the sticky protein. This has allowed them to identify many of the DNA sequences that control

how parasites express only a single *var* gene at a time. "By continuing to dissect this regulatory process, we might be able to discover ways to disrupt it," says Deitsch, "and ultimately interfere with the parasite's ability to cause disease." Recently, Deitsch published a paper on a new methodology for controlling the level of expression of a gene that is inserted into the parasite. With colleagues at


Weill Cornell and Notre Dame, he is using this technique to find out if over-expression of particular genes plays a role in drug resistance. "Since malaria parasites develop resistance to anti-malarial drugs over time and effective vaccines have yet to be developed, we'll always need new drugs in the pipeline," says Deitsch.

Pharmacology professors Lonny Levin, PhD, and Jochen Buck, MD, PhD, are

working with Deitsch to develop inhibitors of an enzyme that the parasite uses to sense changes in pH and carbon dioxide levels; when the enzyme is inhibited, the parasite fails to replicate and eventually dies. Deitsch is also collaborating with associate professor of pharmacology Anthony Sauve, PhD, to investigate proteins that modify the structure of chromatin (the combination of DNA, RNA, and proteins in the cell's nucleus) and are important for *var* gene regulation. Deitsch cloned the version of the protein found in malaria parasites and gave it to Sauve, who is using it as a target for drug development.

Deitsch is also interested in strategies to prevent malaria during pregnancy. Expectant mothers are particularly vul-

Deitsch's research focuses on how the malaria parasite coordinates expression of up to sixty *var* genes. 'It's one of the most fascinating puzzles in all of genetics,' he says.



PROVIDED BY KIRK DEITSCH

Gene pool: *Var* genes are highlighted within the nuclei of two malaria parasites.


nerable to the disease, which increases risk of premature delivery, miscarriage, stillbirth, and low birth weight. A gene called *var2csa* is present in all malaria parasites but is expressed only by those infecting pregnant women, adhering to the placenta. Scientists had long wondered why the gene is never expressed in men or in women who are not pregnant. Recently, Borko Amulic, PhD '09, and Deitsch found that *var2csa* has an extra level of regulation; when the parasite is not infecting a pregnant woman, this regulatory element prevents expression of the gene. "If we could work out the mechanism for keeping that gene silent when you're not pregnant," Deitsch says, "perhaps we could switch it 'on,' so women could make natural immunity and would never get placental malaria." He notes that several groups are currently working on developing a vaccine against pregnancy-associated malaria that is targeted to the protein encoded by this gene.

In the future, Deitsch hopes to study gene regulation in other protozoan parasites such as toxoplasma, cryptosporidium, and babesia. "These important pathogens share many basic biological processes," he says, "so discoveries we make while studying malaria parasites are likely to be applicable to them as well."

— Jen Uscher

Think Big

Gates Foundation grant for unorthodox ideas supports a novel way to study tuberculosis



JOHN ABBOTT

Kyu Rhee, MD, PhD

Most grants are awarded on the basis of past performance—a proven track record that makes a research project seem a solid investment. But the Gates Foundation’s Grand Challenges Explorations program is different: the application is just two pages long and requires no preliminary data. Twice a year, the foundation gives out dozens of \$100,000 awards to

researchers with innovative but unproven ideas for improving global health. The program got more than 3,000 proposals for its second round; it funded eighty-one.

Among those winners was infectious diseases professor Kyu Rhee, MD, PhD. His aim: to lay the groundwork for more effective tuberculosis drugs by studying the most basic properties of the causative agent, *Mycobacterium tuberculosis* (MtB), at a molecular level. “This is an idea that wouldn’t have been fundable by conventional mechanisms,” says Rhee. “It’s extremely high-risk, in that it challenges several long-standing assumptions about MtB without clear knowledge of what the answer will be. Nonetheless, the payoff could be enormous.”

Rhee is particularly interested in studying MtB during the latent stage of TB, when people are infected but show no sign of disease; this represents about one in every three people on the planet. While he says that only about 10 percent of such patients may go on to become ill during their lifetime, this accounts for 8 million cases and 2 million deaths annually. From an epidemiologic point of view, Rhee says, “detection of every symptomatic case of TB is associated with twenty-five new latent cases, so targeting MtB during this stage of infection is central to establishing control of the TB pandemic.”

Worldwide, TB is the leading cause of death from bacterial infection. Although it’s relatively rare in the developed world, it poses devilish problems even for patients with adequate health care. The current course of treatment for active TB calls for two to four drugs daily for a minimum of six months—preferably nine or even twelve. Treatment of latent TB is also lengthy, requiring nine months of therapy with a single agent. But with side effects like nausea, G.I. distress, and possible liver and eye damage, many patients don’t stay the course. “It’s hard to get the average person to take a vitamin every day, so imagine trying to convince someone to take these medications for at least six months,” says Rhee, the William Randolph Hearst Foundation Clinical Scholar in Microbiology and Infectious Diseases. “It’s incredibly complicated and highlights the inadequacy of our current antibiotics against MtB.” He further stresses that’s away and apart from the problem of highly drug-resistant strains, which are on the rise—and the very con-

sequence of this inadequacy.

To address this problem, Rhee and his team considered a fundamental question: How do you develop an antibiotic? Current approaches involve one of two plans of attack. "You can take a molecule and hope to find some type of inhibitor that you could convert into an antibiotic," he says. "Or you can take the rainforest approach, where you dig up dirt from all parts of the world, look for something that kills your organism of interest, and then figure out how it works." After debating which of the two methods was more promising, they realized there was a third route. "We came to the decision," he says, "that neither approach would work effectively until we knew more about the basic biology."

Rather than using technology like microarrays that examine organisms at the genetic level, Rhee and his team have adapted a tool from the physical sciences: mass spectrometry. "Think about how drugs work," he says. "Drugs don't work on genes, they work on proteins and cellular physiology. If you want to make a drug, it may be more useful to study proteins and—

even better—small molecules, because drugs work at that level. It's biology with a practically oriented angle. So we have decided to tackle TB drug development by studying its biology at this pharmacologically relevant level. To date, we've already uncovered some aspects of MtB metabolism that fundamentally differ from that of other microbes and humans, and may hold major implications for current TB drug-development efforts."

Rhee notes that other bacterial infections—even the most life-threatening ones—typically require drug regimens of far less than six months. Understanding why TB becomes so thoroughly entrenched in the body, and how it can remain dormant for so long before becoming infectious, are among his team's goals. If their work bears fruit, the Gates Foundation could provide additional support of \$1 million or more. "TB is a great example of how our existing antibiotics are inadequate," he says. "But without knowing the biology, we don't have much chance of finding better ones."

— Beth Saulnier

'TB is a great example of how our existing antibiotics are inadequate.'

It has long been known that the class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) can cause sexual side effects including decreased libido, erectile dysfunction, and inability to achieve climax. But now, Weill Cornell researchers have found that the drugs can also harm fertility. In a study published in *Fertility & Sterility* in June, urology chairman Peter Schlegel, MD, and colleagues revealed that as many as half of men taking paroxetine, sold under the trade names Paxil and Seroxat, suffer from decreased sperm quality. "This drug can have a substantial effect on the chance of pregnancy occurring naturally and even affects the success of advanced reproductive technologies like *in vitro* fertilization," he says, "but these effects are not detected on a standard semen analysis."


The researchers followed thirty-five healthy male volunteers who were given paroxetine for five weeks. They found that the drug did not affect the men's sperm volume, concentration, motility, or morphology—factors evaluated during semen analysis. But in about half of the subjects, significant numbers of sperm had fragmented DNA; the drug, Schlegel says, likely slows the rate at which sperm travels from the testes to the ejaculatory ducts. "The effect typically occurs by causing sperm to 'hang up' in the body at higher temperatures than normal, causing damage—but not so bad that they are completely destroyed." The study also confirmed the effect of SSRIs on sexual function: nearly half of the participants reported ejaculatory difficulties.

While it's known that women as well as men suffer sexual side effects on SSRIs, it's unclear whether the drugs might also affect egg quality—or to what extent the sperm damage might increase the likelihood of birth defects if conception is successful. Schlegel plans to continue his work on SSRIs and fertility, and investigate how other types of antidepressants may compromise sperm quality. He notes that although paroxetine seems to dramatically curtail male fertility and sexual function, the effect appears to be reversible: the men in the study returned to normal a month after stopping the drug. "It appears to wash out within weeks, but more information is needed," he says. "This is a drug that up to 40 million people in the U.S. take, so there's huge potential interest in this."

— Beth Saulnier

Missed Conception

Study finds that SSRIs compromise male fertility



Father figures: Healthy human sperm



JOHN ABBOTT

Postdoctoral researcher
Yanping Li, PhD, and
Chenjian Li, PhD

Mighty Mice

Tiny transgenic creatures may be major players
in the battle against Parkinson's

When Weill Cornell researchers began creating transgenic mice to model Parkinson's disease, they weren't sure what to expect. Although they were optimistic about the new technology, the genetic mutation that causes Parkinson's is notoriously problematic to transplant. "We were hoping the mouse model would reflect the human form of Parkinson's, and it does," says senior and corresponding author Chenjian Li, PhD, an assistant professor of neuroscience

whose team's findings appeared in the June 7 issue of *Nature Neuroscience*. "After so many failures, there was definitely a feeling of 'Wow, we finally succeeded.'"

Although other researchers have had partial success in creating Parkinson's-affected mice, those engineered in Li's lab are the first definitive animal models of the disease. These new, more accurate mouse models aid researchers on two levels: first, they will enable a mechanistic study of how the disease develops; second, the mice can be used as indicators for drug research.

The mice were modified to express PARK8, a type of Parkinson's disease caused by mutations of a kinase known as LRRK2, which is widely associated with late-onset Parkinson's. "LRRK2 is the most important genetic cause for Parkinson's disease because it accounts for the largest number of cases," says M. Flint Beal, MD, the Anne Parrish Titzell Professor of Neurology and one of the paper's co-authors. "For example, in some special populations it can account for as much as 40 percent; that seems to be the case in North African and Ashkenazi Jewish populations."

Part of the reason a good mouse model of Parkinson's disease has been so elusive, the researchers say, is the complicated structure of LRRK2. The technique that made the difference in their work is called a bacterial artificial chromosome, or BAC. "You take a huge chunk of DNA and inject that into the mouse embryo, which is called a pro-nuclear injection," explains Li, who was part of the Rockefeller University team that originally developed the technology. "And then there is a chance that the DNA is incorporated into the genome." Once a few mice—known as founders—successfully recreate the disease, they are bred naturally.

The animals developed at Weill Cornell express nearly five times the level of the Parkinson's-causing protein. Though the appearance of those phenotypes was encouraging, the team still had to make sure they were accurate models of the disease. Because human Parkinson's is caused by the death of dopaminergic neurons—those involved in transmission of the neurotransmitter dopamine—a common treatment is the replacement of levodopa, a naturally occurring drug lost during cell death. "The mice moved reminiscent of the human condition," Li says, "but to prove the problem is with the dopaminergic system we administered levodopa—and it does alleviate the symptoms."

While it is impossible to directly correlate the lifespan of the mouse to that of a human, the progression of Parkinson's appears to be roughly equivalent. With a life expectancy of around two years, the transgenic mice begin to show significantly arched posture and slowness of movement at about ten or eleven months of age, although the researchers say more subtle deficits occur even earlier. The severity of the disease—and the effectiveness of treatments—is measured by the mice's ability to stay on a rotating rod and perform in open-field tests.


The mice developed at Weill Cornell are already available to labs working on the LRRK2 forms of the disease, and the scientists anticipate the animals will generate new Parkinson's studies. "It's as if we're building a stage for many scientists to perform their plays," Li says. "Because the mouse model recapitulates the human condition

quite accurately, that creates a strong platform for both mechanistic study and drug testing." Ideally, new research will also benefit patients affected by other forms of Parkinson's disease, not just PARK8.

Work also continues on the genetic structure of the Parkinson's mice. "There are some features of the mice that don't completely replicate idiopathic Parkinson's disease," says Li. "For example, they haven't developed overt large aggregates of Lewy bodies, a pathologic hallmark of Parkinson's disease; instead, they may have micro-aggregates."

In a recent advance, Li's lab successfully developed a new technology that allowed them to create transgenic rat models of the disease. Rats have many biological characteristics that are closer to human and are more sensitive to insults to the brain. "We are still in the basic research stages," Li stresses. "It's a nice step, but it's only the first one on a very long road."

— Liz Sheldon



PROVIDED

On the mind: Mice with the LRRK2 mutation show neurite degeneration in the same dopaminergic system as humans with Parkinson's disease.

Common Cause

By Beth Saulnier

Photographs by John Abbott


The Clinical and Translational Science Center aims to get researchers out of their 'silos,' promoting collaboration across disciplines—and institutions

W

hen Stefano Rivella, PhD, delved into the genetics of the blood disorder known as Cooley's anemia, his preliminary data was highly promising—opening up what he calls “a positive Pandora's box of scientific discovery.” But although the project was going well, he recalls, “I was touching on subjects where I wasn't completely an expert.” In the hope of finding the right collaborator, the associate professor of genetic medicine in pediatrics decided to try something unorthodox.

hen Stefano Rivella, PhD, delved into the genetics of the blood disorder known as Cooley's anemia, his preliminary data

In October 2008, Rivella was among more than eighty basic and clinical scientists who attended the Translational Research Bazaar; the event was modeled on the concept of speed dating, in which singles rotate among prospective partners for brief conversations. But instead of romance, participants had research on their minds. Clinicians, who sat on one side of a long table, had about three minutes to discuss their work with basic scientists before a bell signaled it was time to move on. After thirty-five such rounds, the researchers had the chance to mingle during a reception; 85 percent later



Jonathan Bourne, PhD candidate

reported that they'd found someone they'd like to work with. Among the matches made that day was Rivella's collaboration with Nancy Greenbaum, PhD, a professor of structural biology at Hunter College. Working with her and other collaborators, Rivella is moving closer to a cure for Cooley's anemia, one of the world's most common inherited diseases. (See related story on page 14.)

Facilitating such bench-to-bedside research is the core mission of the consortium that hosted the research bazaar: the Weill Cornell Clinical and Translational Science Center (CTSC). Founded in September 2007 with a \$49 million grant from the National Institutes of Health, the CTSC is one of forty-four such centers nationwide—multidisciplinary, trans-institutional entities that bring together researchers and clinicians from disparate disciplines to broaden scientific knowledge, tackle pressing medical issues,

and promote community health. Headquartered on East 61st Street, the CTSC unites the health-care institutions in the Upper East Side neighborhood affectionately known as "bedpan alley": Weill Cornell Medical College and Graduate School of Medical Sciences, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, Hospital for Special Surgery, Hunter College School of Nursing, Hunter Center for Study of Gene Structure and Function, and Memorial Sloan-Kettering Cancer Center, in addition to Cornell's Ithaca campus and its New York City Cooperative Extension office. "It's an initiative to bring together researchers from different institutions with different ideas to collaborate and facilitate discoveries," says Julianne Imperato-McGinley, MD, the CTSC's program director and Weill Cornell associate dean for translational research and education, "and then move those

Julianne Imperato-McGinley, MD



discoveries out to the community and the public.”

One of the primary ways in which the CTSC aims to accomplish its mission is by offering seed money to investigators, and it has funded dozens of pilot projects since its inception. Rivella was among the early recipients. “Many times, when you apply to granting agencies, you need a lot of preliminary data to convince the reviewers that your work is sound,” he says. “The pilot award is a fantastic tool, because you can go to the CTSC with a good idea, but you don’t necessarily need to have a lot of the work done that you need to apply for other grants. We’re now writing a paper and applying for another grant, which we couldn’t have done if the CTSC had not helped us.”

Another early pilot award went to Weill Cornell’s Ronald Silverman, PhD, and Hunter physicist Ying-Chih Chen, PhD, to support their work on improving the resolution of ultrasound images of the eye via photo-acoustic technology. Echoing Rivella, Silverman says the pilot award opened doors for a bright idea whose promise was unproven. “It’s unlikely we’d have ever gotten started without the CTSC,” says Silverman, a research professor of computer science in ophthalmology. “Coming to the NIH with an idea and no real preliminary data, you’re just not going to get funded; the system doesn’t work like that. The CTSC gave us seed money to do pilot experiments and get some infrastructure together.”

The grants are only one element of the CTSC. Others include its Clinical and Translational Education Program, which currently comprises more than fifty students. Those attending for one year earn an advanced certificate in clinical investigation; if they continue for a second year, including electives and a mentored research project, they earn a master’s degree. The program also offers an MD-PhD, an MD-MS, and modular training in clinical research methodology, holding seminars on such topics as drug and medical device development.

“Part of what’s so fascinating about the CTSC is that it spans departments and disciplines,” says Jonathan Bourne, a PhD candidate in physiology, biophysics, and systems biology who is also earning a master’s in clinical investigation. “You have biomedical engineers and biochemists, and at the other end of the spectrum you have practicing physicians doing clinical research. If I have a question about oncology, I can grab one of the MDs and say, ‘Here’s what I’m looking at, here’s what I was thinking, is this medically correct?’ And for the MDs, the PhDs provide a different point of view. I’ve seen talks where a rheumatologist or an oncologist presents some work, and from a basic science side we can say, ‘Have you thought of this mechanism? Have you thought about how fluid flow might be changing drug delivery?’ It provides an umbrella to bring together all of these different areas and specialties within a unified and coordinated center.”

The CTSC also hosts a variety of events, like the research bazaar, that promote collaboration or facilitate investigation. A pasta dinner at the Griffis Faculty Club drew some sixty-five scientists from CTSC partner institutions for lessons in the role of intellectual property in biomedical research; speakers included Alan Paa, Cornell University’s vice provost for technology transfer and economic development. In September 2008, the CTSC emphasized another of its goals—to encourage community organizations to participate in clinical and translational research—with an event devoted to increasing community engagement; more than 100 people attended, including representatives from faith-based groups, health departments, and medical institutions. Partnering with the Hunter Gene Center, the CTSC co-sponsored a symposium—“Translational Cancer Research: Bench, Bedside, and Community”—that drew more than 250 people to the Hunter campus.

For researcher Darshana Dadhania, MD, and her colleagues, the CTSC has been the source of invaluable logistical support as they’ve searched for urine biomarkers indicating renal transplant rejection. Through the Clinical and Translational Research Unit—which features laboratories, inpatient and outpatient facilities, and nursing and support staff—the researchers have a centralized location for biopsies, blood sampling, and patient monitoring. “The CTSC allows us to standardize our procedures and serves as a central resource for our research studies,” says Dadhania, an assistant professor of medicine. “The CTSC support was invaluable in completing the largest translational study in transplantation at New York-Presbyterian Hospital/Weill Cornell Medical Center.”

The nationwide collection of clinical and translational centers is the brainchild of former NIH director Elias Zerhouni, MD; as head of the agency, he called on medical researchers to challenge their traditional “silo” approach, in which specialists are isolated in their own disciplines. The NIH Roadmap for Medical Research, announced in 2003 and launched the following year, aims to break down barriers that limit discovery via such initiatives as the agency’s Clinical and Translational Science Awards Consortium, of which the CTSC is a member. “In today’s world, we realize that disease is a complex entity,” says Imperato-McGinley. “For instance, take diabetes. You have genetics, nutrition, economics—many factors that feed into one condition. So it’s clear that you need teams of researchers working on all aspects of the disease; you have to look at it in its entirety. That’s what Dr. Zerhouni and the Roadmap initiative are trying to do: let everyone get together, talk about it, work on it, develop the ideas. That’s the key to modern research.”

The following is a sampling of research projects funded or facilitated by the CTSC.

The Endoscope Meets the Multiphoton Microscope


Two decades ago, Multiphoton microscopy was developed in the lab of Ithaca-based applied physics professor Watt Webb, ScD. Now, researchers there and at Weill Cornell are working together to adapt the technology for human diagnostics—specifically, the detection of cancer in its earliest stages. “You can image live tissue without using contrast or processing it in any way,” says Sushmita Mukherjee, PhD, an assistant professor of biochemistry at Weill Cornell and the director of the Multiphoton Microscopy Facility there. “So the idea is eventually to miniaturize this into an endoscopic format and be able to image in real time in a live patient.” Among Mukherjee’s collaborators: her former postdoctoral mentor, Frederick Maxfield, PhD ’77, the Horowitz Distinguished Professor of Neuroscience. “This is innovative—and, from a granting point of view, somewhat risky,” he notes. “We’re not just doing things a little differently from what people have done before. We’re doing things that nobody ever tried, and we don’t always know if they’re going to work.”

In collaboration with surgeons and pathologists, Mukherjee has been focusing on bladder cancer, using fresh human tissue (obtained from biopsied or excised organs), which she views via a Multiphoton microscope that Ithaca-based biomedical engineering professor Warren Zipfel, PhD, custom built for the Medical College several years ago. “We image them, and the same piece is submitted to the pathology department for a standard diagnostic workup; then we compare our data with the pathology analysis, which is the gold standard,” Mukherjee says. “Our goal is to build what we’re calling a ‘Multiphoton human pathology atlas’ that has images of different organ systems that have been taken with Multiphoton microscopy and images of the same tissue that have been taken from stained slides prepared for conventional histopathology, so one can compare and contrast and see whether Multiphoton imaging has the same diagnostic potential.”

Meanwhile, engineers in Ithaca have



Sushmita Mukherjee, PhD



Double vision: A bladder tumor seen at various levels of magnification via Multiphoton microscopy (green) and gold-standard histopathology (purple)

been working to miniaturize a Multiphoton microscope for endoscopic use; Mukherjee says a prototype is expected by this fall. “It’s a conceptual leap, but if it pans out—and there are many technical hurdles—it is going to revolutionize the patient experience,” she says. “Today, during an endoscopic procedure, if something looks suspicious, the only option the surgeon has is to biopsy or resect the area ‘to be safe.’” Many of these regions, on later histopathological diagnosis, turn out to be benign or simply inflamed, Mukherjee notes. Since each additional biopsy or resection increases both cost and risk to the patient, a real-time inspection of the suspicious area by Multiphoton imaging is likely to aid surgical decision making. “This, in turn, is likely to reduce the number of unnecessary biopsies, thus reducing procedure cost and improving the patients’ experience,” she says. “Also, given the real-time nature of this imaging modality, it is possible to visualize a scenario in which the patient can leave the endoscopy suite knowing whether they have cancer, and, if so, what’s in store for him or her in the coming weeks and months, depending on the exact stage and grade of the tumor.”

After Kidney Transplant, a Safe and Easy Test for Rejection



Darshana Dadhania, MD

For transplant patients, receiving an organ is both a cause for celebration and the beginning of a lifelong relationship with immunosuppressive drugs—and the prospect that their bodies might reject the organ is an ever-present worry. But if work by a team of Weill Cornell researchers fulfills its promise, such patients can look forward to less invasive, more individualized treatment. In studies first published in the *New England Journal of Medicine* in 2001, Manikkam Suthanthiran, MD, and colleagues have been searching for biomarkers that indicate potential allograft rejection in kidney transplant patients. “By measuring certain genes in the urine of transplant patients, we can diagnose rejection with a high degree of accuracy—85 to 90 percent sensitivity and specificity,” says Suthanthiran, the Stanton Griffis Distinguished Professor of Medicine. “We anticipate these studies will make a substantive impact in managing transplant recipients.”

The results of the initial work at Weill Cornell led to an NIH-sponsored five-center study comprising nearly 500 renal-transplant patients, and the initial results are very promising, the

researchers say. The urine biomarker method is already being used at NYPH/WCMC to monitor patients as part of an NIH-sponsored research project, and Suthanthiran hopes it will be developed as an FDA-approved test for clinical care within five years. The new method could offer patients a quick, painless way to check for rejection, currently diagnosed via biopsy. “A major interest for the transplant community is to develop a noninvasive procedure,” says Suthanthiran, noting that biopsies are not only costly and time-consuming but run the risk of bleeding and infection. “The transplant immune response is not a one-shot deal, it’s day to day. Like blood pressure or blood sugar, you need to monitor it on a continuous basis. A non-invasive test would take the level of care to one that can never be accomplished otherwise. Nobody can biopsy a patient every month for the rest of their lives.”

The biomarker test—which could potentially be adapted to other organ-transplant recipients using peripheral blood or urine—would also allow doctors to diagnose problems earlier, getting a head start on treatment and potentially staving off rejection. “Serial studies to look at how early we see the changes in the biomarkers before permanent damage begins to take place in kidney transplants are in progress,” says Darshana Dadhania, MD, an assistant professor of medicine, “but I would say we expect to have a lead time of weeks to months, depending on the pathology.”

According to Suthanthiran, perhaps the most valuable element of the new monitoring system would be the ability to offer individualized drug therapy. Patients who show no signs of rejection could be put on lower doses of immunosuppressants, reducing the risk of side effects. Twenty years post-transplant, Suthanthiran notes, 25 to 30 percent of patients are diagnosed with cancer, and infection is a constant concern. “Right now immunosuppressive therapy is one-size-fits-all—everybody gets a certain amount,” he says. “We believe that this type of test will allow us to personalize immunosuppressive therapy and minimize the threat of complications such as cancer and infections.”

Researchers Design 'Dots' That Detect Cancer

Michelle Bradbury, MD, PhD



In a collaboration between two Cornell campuses, researchers have been developing some of the tiniest warriors in the battle against cancer. Working with Ithaca-based engineers, radiologist Michelle Bradbury, MD, PhD, has been developing targeted nanoparticle probes that could be used to diagnose and target tumors. Nicknamed “Cornell dots,” the probes were created in the lab of Ulrich Wiesner, PhD, the Spencer T. Olin Professor of Materials Science and Engineering.

Each dot, consisting of dye molecules encased in a silica shell, is on the order of six nanometers in diameter—a nanometer being one-billionth of a meter. The probes are coated with polyethylene glycol,

which helps prevent the body from recognizing them as foreign. The shell can be covered in molecules designed to attach to tumors, and the dye fluoresces under near-infrared light emission, identifying areas of malignancy. “Silica is by its very nature something that we ingest in our diets,” notes Bradbury, whose primary appointment is at Memorial Sloan-Kettering Cancer Center. “I wanted to pick something that I thought had a good chance of going to the clinic, because I’m a clinician and a scientist—so that whatever we develop could potentially be taken to the clinic in the long term.”

In their study of melanoma tumors in a mouse model, the researchers explored the dots’ effectiveness using both optical and PET imaging. The results, she says, were highly promising. “We showed that the platform was non-toxic and biocompatible, cleared efficiently through the kidneys, and demonstrated high tissue signal—all characteristics that would permit it to go to the clinic as a next step,” Bradbury says. “In imaging, we have some contrast agents that have been around for decades, which are not specific for any particular disease. More recently, relatively small numbers of molecular agents have been developed that can directly target specific tumor types, but we need to develop a larger array of compounds for evaluating a broader range of diseases.”

The potential of the Cornell dots is not limited to imaging; they might also be used for drug delivery or advanced diagnostics—for instance, measuring tumor pH levels. Additionally, other diseases, such as infectious/inflammatory states, may be the subject of future investigations. Within a year, Bradbury and her colleagues expect to launch an initial clinical study of the probes’ tumor-detection potential. “Everyone talks about personalized medicine, but how do you optimally achieve that?” she asks. “One way to achieve this goal is by developing platforms that allow you to target tumors specifically—and deliver therapies or monitor site-specific biology without concerns of associated toxicity.”

Exploring the Biomechanical ‘EMK Effect’

Jonathan Bourne is conducting research that could ultimately have implications for a wide variety of patients—from diabetics to the elderly to athletes who’ve torn an Achilles tendon. Bourne is a PhD candidate in physiology, biophysics, and systems biology working under biomechanics professor Peter Torzilli, PhD, in the Laboratory for Soft Tissue Research at Hospital for Special Surgery. Bourne is studying the protective qualities of mechanical force on collagen tissues, such as tendons and ligaments—what the lab has termed an enzyme mechanokinetic (EMK) effect. “If we understand how the human body is able to slow or change the rate at which these structural tissues are broken down, it provides important information about diseases such as osteoarthritis,

Achilles tendon ruptures, ACL repairs,” Bourne says. “It helps us understand how and why grafts are resorbed by the body, and how to change those processes. So on the basic science side, we’re looking at structural modeling of proteins. And on the translational side, we’re looking at how changes that are age related or increased by diabetes—called glycation, which is sugar cross-linking of tissue—to understand how they change the biological process and this protective EMK effect.”

Sugar cross-linking is part of aging, causing tissues to stiffen; diabetes, marked by high blood glucose, speeds up the process. But mechanical forces, or “loads”—exerted by tissues against each other—seem to protect against it. Bourne is currently focusing on how such factors

affect the tendon grafts commonly used to repair ACL injuries. “We’re trying to understand how tendon tissue responds to this sort of abnormal situation and how loading or unloading this tissue might better control the rate at which the body turns the graft into a repaired tissue,” he says. “Orthopaedic surgeons had revealed long ago that load is good. They said, ‘The graft has to be in tension,’ but they never pegged down a specific number. Our work actually describes a certain threshold value for this protective effect to kick in. It’s almost an on/off switch.”


The work of Bourne and his colleagues could lead to a variety of advances, including improved techniques in surgery, physical therapy, and postsurgical care. It could also point the way toward drugs that replicate the protective EMK effect. “There could be chemical or pharmacological agents to reverse the cross-linking,” he says. “So it provides an easy target for future applications to change the biology of the process.”

Viewing the Eye, at the Speed of Light

You can't image deeply in tissue with light very well," says Ronald Silverman, PhD, "because when light enters a tissue it starts to get scattered quickly." As an example, the Weill Cornell research professor of computer science in ophthalmology cites the view of a human hand covering a flashlight. "You can see the light coming through, but your hand looks like a blurry pink thing," he observes. "It's not like an X-ray. Just shining light at tissue doesn't get you a nice optical image."

But Silverman and his colleagues are working to harness light—in extremely small slices—to create a better method for viewing the human eye. Through a technique called photo-acoustic imaging (also known as opto-acoustic imaging), a pulsed laser is paired with ultrasound to target specific molecules—say, hemoglobin—that absorb light at known wavelengths. "The photo-acoustic effect was actually discovered by Alexander Graham Bell in the nineteenth century," Silverman says. "So it's been known that if you shine a bright light in a short pulse and it's absorbed by something, you'll generate a sound wave. But it's only in the last decade or less that interest has taken off."

With Hunter College physicist Ying-Chih Chen, PhD, Silverman has been working to design an imaging method that could provide potentially more detailed views than current technologies, such as optical coherence tomography (OCT). "We put together a proposal to develop a system designed specifically for the eye and other superficial tissues, like skin," Silverman says. "The unusual approach we proposed was to use a focused laser. For photo-acoustic imaging you don't have to focus the laser; the only requirement is that the laser



PROVIDED BY RONALD SILVERMAN

In focus: A pig eye is seen in a conventional ultrasound format (A) and a photo-acoustic image (B). In the ultrasound image, the cornea, lens, and iris are labeled by first letter.

have a very short pulse—we're talking nanoseconds, one-billionth of a second. But by focusing the laser, we could create a spot that was smaller than the focus of the ultrasound receiver. This would give us the kind of resolution that people get with OCT, but we'll be able to see deeper, because in OCT once the light is scattered, the signal will blur out."

Silverman hopes the technology could offer better views of such structures as the choroid, which supplies blood to the retina and is suspected to be the point of origin for macular degeneration, the most common cause of blindness in people over sixty-five. "It would also be relevant for glaucoma, if we could image the circulation in the optic nerve area," he says, "because many people believe that the damage that leads to vision loss is caused by ischemia."

But he notes that photo-acoustic imaging has applications far beyond the eye. In fact, most of the work on the technology has been done in relation to breast cancer. Others have explored its use in animal models of cancer, and Silverman himself is interested in using it to study melanoma—which exists not only as a skin cancer but an intraocular one as well. Currently, he and Chen have a proposal out to the NIH, hoping for a four-year grant to continue their work. "The goal is that at the end of the proposed project, we would have a system ready for clinical studies," he says. "We have to make sure that it will be at light levels that are within federal guidelines for laser safety, which we think we can do. And we have a bunch of other problems to solve—but they're all solvable."



Ronald Silverman, PhD

Korean Immigrants and Depression

Researchers have long known that immigrants are twice as likely as the general population to suffer from depression. In a recent study, Hunter College nursing professor Kunsook Bernstein, PhD, examined how those rates are reflected in immigrants—particularly those who, like her, came to the U.S. from Korea. “We decided to launch a prevalence study to see how immigrants are adapting to the culture and how it has an impact on their mental health, and depression is one of the common mental health issues,” says Bernstein, a board member and research chair of the Korean American Behavioral Health Association. “But most immigrants don’t seek help, because they look at it as part of their way of life and just bear it.”

With the help of Korean community organizations like churches, senior centers, and college student groups, Bernstein disseminated a questionnaire that explored

issues of mental health, cultural assimilation, and discrimination. She got about 300 usable responses—and found that, in fact, the rate of depression (13.2 percent) was more than twice that of the general population. (The study only targeted adults; about 60 percent of respondents were female, and the researchers found no difference in depression rate between the genders.)

Among the most significant factors in immigrants’ tendency to depression, Bernstein says, are education, income, and language proficiency; those with higher levels are less likely to be depressed. “It has to do with their adaptation skills,” she says. Her study also confirmed that Koreans, like many immigrants, are often reluctant to seek mental health treatment. In collaboration with Heejung Bang, PhD, a Weill Cornell associate professor of biostatistics in public health, Bernstein has



**Kunsook
Bernstein,
PhD**

since put in another grant application to the CTSC for a study of the barriers preventing people from asking for help. In another project, funded with a small grant from CUNY, she has been exploring the potential of autobiography as a therapeutic outlet for Korean immigrant women. “The Western style of psychotherapy does not work well with them,” she says. “But if you ask them to write their life stories, they can find meaning and purpose in their lives.”


Seeking to Reduce Arthritis After ACL Reconstruction

Each year, some 80,000 surgeries are performed nationwide to reconstruct the anterior cruciate ligament (ACL). The ligament—the vital “rubber band” crossing the knee—is commonly injured by athletes such as skiers or basketball players who stop and turn suddenly. At Hospital for Special Surgery, which performs 700 to 800 of the operations each year, mechanical engineer Carl Imhauser, PhD, is studying the biomechanics of various strategies for ACL reconstruction. His goal: to reduce the incidence of osteoarthritis (OA), which commonly strikes patients a decade or two after surgery. “That’s important, in that the people who tear their ACL are usually young,” says Imhauser, a postdoc in the department of biomechanics. “Someone who has surgery at thirty and gets OA ten years later still has half his life in front of him or her.”

Imhauser notes that the human body is a load-bearing structure, operating under the force of gravity—and that even the most skilled surgical reconstruction involves upsetting the delicate interaction among its cartilage, ligaments, and bones. “OA deals with the breakdown of cartilage, the tissue in your joints that allows the joint to move smoothly,” he says. “The health of that tissue is intimately related to the loads that it sees. If those loads are altered, over time you see the onset of OA. But if we can characterize how loads are transferred and target surgeries that best restore normal patterns, then maybe we can help people avoid going down that path.”

Imhauser’s work includes experiments with cadaver knees, which are mounted on a robot that can move in six degrees of freedom. “It can push or twist the joint in basically any direction and allows us to

precisely measure how the joint moves in response to those forces,” he says. He’s also using the robot to evaluate predictions from a computer model; the model allows him to manipulate a virtual knee joint and see how various surgical approaches would affect the function of the joint. Such work—which could also be applied to other orthopaedic procedures, such as design of knee replacements or meniscus repair—could ultimately allow surgeons to tailor their techniques based on a patient’s anatomy. “Each of us has unique bony geometry and ligament structure, which dictates how we move and how loads are transferred across the joint,” he says. “For patients with a certain shape of bone and ligament structure, you might be able to say, ‘This kind of reconstruction is most appropriate.’” ●



Carl Imhauser, PhD

Female scientists
confront the challenges
of gender in
academic medicine

To Shatter the Ceiling

By Sharon Tregaskis
Photographs by John Abbott

Professor of medicine Babette Barbash Weksler, MD, arrived at Weill Cornell in 1968 as a hematology fellow. In the ensuing forty-one years, the clinician-scientist (and grandmother) has developed an international reputation as an expert in platelet and endothelial cell biology, enjoyed long-term research support from the National Institutes of Health and the American Heart Association, and served at a leadership level in the American Society of Hematology.



On a recent sabbatical in France, Weksler developed a novel endothelial cell line that scientists can use to model the blood-brain barrier, a critical structure for brain health that challenges drug delivery for everything from chemotherapy to treatments for Alzheimer's and depression. Jointly patented by Cornell and the Parisian Institut Cochin, where she spends part of each year, the cell line is now in use by more than 100



research labs around the globe. “After all these years I still find it exciting and stimulating,” says the professor, who splits her time between caring for hematology patients and the lab. While most of her classmates from medical school and college are enjoying more leisurely activities, Weksler admits that she still sits up late into the night reading literature in her field. “To be paid to do what you like is a great privilege.”

Women’s work: Developmental and cell biology chair Katherine Hajjar, MD (center), in the lab with students (from left) MaryAnn Dassah, Caroline Greenberg, and Dena Almeida.

As a child, Weksler had plenty of evidence that women can thrive in medicine and enjoy a rewarding personal life. Her maternal grandmother trained at Cornell when the medical school was still upstate, then transferred to a program in Boston because there weren't enough patients in Ithaca to support the private nursing she did to put herself through school. Weksler's mother, an allergist, worked in private practice. By the time Weksler started her fellowship, she was married to Marc Weksler, MD, now the Irving Sherwood Wright Professor of Geriatrics and professor of medicine at Weill Cornell, and their children—both born before Weksler finished her first year of medical school—were in school in New Jersey, where the family made its home.

It wasn't easy juggling her dual roles, says Weksler, who once aspired to a career as a hand surgeon but abandoned the dream due to the extended training. "It was the usual kind of circus to make sure there was a stable nanny," she says. "Sometimes there was, sometimes there wasn't." These days, at least, patients rarely address Weksler as "nurse," as they often did early in her career. But even though she rose to full professor in 1981 and helped train Barbara Hempstead, MD, PhD, the current co-chief of the Division of Hematology and Medical Oncology, she observes that the overall prospects for women in the upper echelons of academic medicine are still bleak. "The power structure remains biased against women," says Weksler, who created her own antidote to the old boys' network in the form of a nationwide web of female collaborators. "Women in the academic pipeline are as productive as men, but they often aren't given as much laboratory space and they're promoted more slowly."

It's been nearly five years since then-Harvard president Lawrence Summers sparked a public furor when he wondered aloud about women's innate capacities in math and science—and while undergraduate women now match their male peers numerically in most science-based majors, the numbers don't hold up as they proceed through the ranks of academic medicine. In 2006 the National Academy of Sciences issued a 346-page report, *Beyond Bias and Barriers: Fulfilling the Potential of Women in Academic Science and Engineering*, authored by a committee of university presidents, provosts, and government officials. Women constitute a scant 15 percent of the nation's life sciences faculty, the study notes, and the problem goes far beyond the challenge of balancing career with motherhood or a shortage of young women coming through the educational pipeline. "It is not lack of talent, but unintentional biases and outmoded institutional structures that are hindering the access and advancement of women," the NAS committee concluded. "Neither our academic institutions nor our nation can afford such underuse of precious human capital in science and engineering. The time to take action is now."



Debra Leonard, MD, PhD

In June 2008 Dean Antonio Gotto, MD, declared that full professorships for women would be among his top priorities for the next five years. While women are well represented at both instructor and assistant professor levels at Weill Cornell, he noted, they lag far behind men as associate professors and, most notably, as full professors. Currently there are 439 female professors on the faculty compared with 645 male professors—and only two department heads are female. "We will be vigilant in finding ways to increase the promotion of women to associate professor and tenured professor," Gotto said. "This is a top priority."

This year, Weill Cornell launched a program dedicated to addressing the issue: the Office of Faculty Diversity in Medicine and Science, which opened in July. Its mission, Gotto said, is expressed by the acronym IDEAL: "To create a palpable culture of Inclusive-ness, Diversity, and Equity in Academic Leadership" at Weill Cornell. "This culture," he said, "will be created through recruitment, mentoring, promotion, retention, and selection for leadership roles to develop and sustain a diverse faculty."

The office will be led by pathologist Debra Leonard, MD, PhD, as Chief Diversity Officer; public health professor Carla Boutin-Foster,

'Most men don't know the balancing act often required of women in academic medicine, so as mentors to women they don't even ask about relevant issues and ways to address them.'

MD, as Director for Diversity in Medicine and Science; and surgeon Rache Simmons, MD, as Director for Women in Medicine and Science. During the 2009–10 academic year, Gotto said, the three will develop plans for the office—among other activities, conducting a faculty survey and holding small group meetings to identify important issues and find the best ways of addressing them. The office's efforts dovetail with those of the American Association of Medical Colleges, which announced this summer that it would form two new professional development groups—one on women in medicine and science, the other on diversity and inclusion—as well as a new committee on diversity affairs.

As Weill Cornell's diversity office gears up, women at the Medical College continue to develop the ad hoc strategies that have helped them cope with the challenges facing female scientists. Hempstead, for example, leverages the flexibility of combined research and clinical responsibility to make life easier for the junior scientists in her department. "We try to be accommodating," says the hematologist, who frequently put her kids to bed and then dashed back to the lab in the evening to get a head-start on the next day's work during her years as a fellow and young mother. "When you accept graduate students into your lab, you're not quite adopting them, but almost. The same goes for fellows." That doesn't mean compromising on the quality of the work they produce, says Hempstead, but rather insuring that they'll persevere in the cycle of research, mentorship, and creation and dissemination of new knowledge. "It's more a question of how can you accommodate their day-to-day family needs so they can get the training and education to be stellar physicians, clinicians, or scientists," she says. "With some flexibility, everybody ends up winning. You get dedicated individuals coming out of the pipeline who will be better mentors to the next generation."

Leonard, who serves as vice chair of laboratory medicine, sees mentorship of young faculty as a critical piece of the puzzle. "Recruiting and startup packages cost a lot of money," she says, noting that a revolving door of young faculty can be an expensive proposition, making retention just as important as recruitment of diverse candidates. "We have the women, we just need to mentor them appropriately so they stay and become associate professors."

That sounds straightforward, but with a paucity of senior women, most of them already stretched thin, many young female scientists end up with male mentors. In some respects such relationships can yield enormous benefits, but they also pose unique disadvantages, says Leonard, who never had a female mentor herself and has made a point of hosting regular gatherings for female graduate students. "With a male mentor, you can't go to dinner together, you can't go for drinks—care must be taken to assure that the reality and the perception are that the relationship is purely professional," says Leonard, who heads the department's residency program. Further, she notes that because men haven't faced the issues women must

confront in their careers, they often lack the insight to guide female mentees. "Most men don't know the balancing act often required of women in academic medicine," she says, "so as mentors to women they don't even ask about relevant issues and ways to address them."

Katherine Hajjar, MD, the Brine Family Professor of Cell and Developmental Biology, has headed her department since 2002, hiring nine junior faculty and boosting the proportion of women to two-thirds of the total. "As chair I'm making sure those six female assistant professors have everything they need to ascend the ladder and get paid at the same rate as the men," she says. "I've tried to protect all of the new assistant professors from major teaching responsibilities until they're more established, after the first two or three years—these are people who need to get grants to support their research programs, and so far, everyone is funded." Part of the problem, says Hajjar, boils down to a statistic from the 2006 National Academy of Sciences report: many more male faculty in

Babette Barbash Weksler, MD





Barbara Hempstead, MD, PhD

How to Level the Playing Field

Advice from faculty women

When their children were young, professor of clinical medicine Anne Moore, MD, and her husband, a physician in private practice, rented a house to which they drove on weekends. A senior colleague invited Moore to collaborate on a project, and he suggested she borrow his strategy of doing dictation while his wife drove to their weekend getaway. "I thought, Oh my God, I don't think you know what I do. He had no idea."

It was a different era, says the oncologist, whose children are

now in their thirties, but the basic challenge remains: How do you devote the same amount of time and effort to the academic world as a male colleague when you work a second shift at home? "I don't know that there's any way around it," says Moore, a former director of the American Board of Internal Medicine. "Women are given a lot of opportunities, but they've still got the bare-bones facts: if you're having babies and cooking dinner and running the house, there's less time for writing papers in the evening."

Institutions can make it easier for women to find the balance, say Weill Cornell's female scientists. Among their recommendations:

Facilitate childcare. "Having access to high-quality daycare so you can be confident that your baby will be in a good situation is key," says hematologist Barbara Hempstead, MD, PhD, who still recalls the day more than two decades ago that a senior colleague heard her tale of childcare woe and scrawled the sanity-saving phone number for an emergency nanny service on a pad of paper. "There's also a need for after-school programs, programs for kids on school holidays. Any way that can be

facilitated ultimately gives you happier, more productive faculty members who are less distracted by day-to-day concerns."

Offer local, affordable housing. During her postdoctoral fellowship, Hempstead and her husband lived close to Weill Cornell. "I could put the kids to bed, run back to the lab and feed some cells, and get a leg up on the next day's work," she recalls. "It afforded tremendous flexibility." Today, she says the Medical College's housing offerings—all within fifteen minutes of 1300 York Avenue—boost recruitment and retention. "It's a perk that helps us attract and retain quality job candidates on almost all fronts."

Stack the deck. Make sure the committees hiring faculty and setting policy reflect the kind of diversity the institution seeks. "We don't recruit enough women in high-power positions," says Randi Silver, PhD, the Graduate School's dean of students. "That's because the search committees are male-dominated. They tend to be senior men and they're looking for guys like themselves. It's a cultural thing. You have to change the culture." Katherine Hajjar, MD, the chair of Developmental and Cell Biology, agrees. "It's critically important that we have

several women on every search committee—and every committee, period. We need to make more of an effort. It's not enough just to put an ad in the *New England Journal of Medicine* and see what comes in. You have to call around the country and say, 'Thanks for sending these names, but are there any women who come to mind?' The more women we get at the upper levels, the more will come."

Improve research support. "One of the wonderful things about being a scientist is that at some level, you're your own boss," says Hempstead. "You're limited only by your creativity and the tools you have to answer interesting questions. Those are rare and wonderful jobs. The part that makes me most wistful is that you bring along graduate students to have those same aspirations, but the current funding environment makes the future much more daunting."

Highlight successful female scientists. "Women sometimes feel that there are no role models," says Hajjar. "If you're at an institution where there are very few women at the senior level and they are working like a dog at work and at home and never coming up for air, those people who are really amazing are invisible."

In the meantime, senior faculty women suggest a few personal tactics for their younger colleagues:

Choose a partner who gets it. As co-chief of hematology and oncology Barbara Hempstead puts it: "When you're a scientist writing a grant, you're working sixty-plus hours a week, almost flat-out, and you need a spouse who will assume—with a nanny or housekeeper—virtually all of the childcare for a couple of weeks and not lose their mind."

Hire helpers. "Women don't always realize the value of paying for more help," says Moore, who had a live-in nanny as backup in case both she and her physician husband were called out of the house simultaneously. "Get a cleaning woman, get the food cooked. There's a lot that women think they need to do themselves, and you just have to give up and hire someone."

Establish a robust local network. "Women have to give some thought to where they end up," says Silver. "Do they have a support system nearby? You can make it work for you with supportive family and a spouse who believes in what you do."



Cristina Fernandez, PhD '08

the biological sciences have partners at home who don't work. Few woman scientists have that luxury. "The men have a wife at home, taking care of the kids," says Hajjar, who credits support from her biochemist husband, graduate school dean David Hajjar, PhD, as a critical element of her own career success. "Institutions need to step up. For example, support for men and women who are in the position where they have to provide childcare or elder care should be a consideration."

But there's another hurdle to women's ascension through the faculty ranks, one over which Weill Cornell has limited control: reduced access to federal research support for all junior faculty. "It's one thing to look at the current funding situation through the eyes of a fifty-some-year-old woman and realize that it's been this bad before and it got better and eventually it will probably get better again," says Hempstead. "But it's awfully daunting if you are a twenty-eight-year-old woman with a baby just getting your thesis done and wondering, How am I ever going to do this? The people who are most vulnerable are the emerging scientific generation. I'm afraid those are the individuals we're going to lose."

For Cristina Fernandez, PhD '08, gender was never an issue in her training as a pharmacologist—her decision not to pursue a career in academic medicine came about in no small part because of the finances of the field. "If there were more funding available, more opportunity, everything would change," says the thirty-year-old. "If you have to be in the lab eighty hours a week, something has to give. If there's more funding, more opportunity, there's less competition, less demand to devote so much time to work."

In her current position as a medical writer at Ogilvy Healthworld, Fernandez works forty to fifty hours a week in an office staffed almost exclusively by female PhDs. "I can't go out for a two-hour cup of coffee or roll in at 10 a.m., but at the same time, very rarely do I have to work weekends or nights." That simple fact has yielded a different kind of flexibility. "I live and work in Manhattan," she says, "but I don't have to be across the street from where I work anymore, because weekends and nights are mine." ●

Worth a Pound of Cure

Physician-scientist Andrew Dannenberg, MD, collaborates with scientists around the globe in the quest to prevent cancer

A

By Beth Saulnier

Photographs by John Abbott

Andrew Dannenberg, MD, has spent the past two decades studying cancer. He has approached the disease from bench to bedside, explored its relationship to everything from smoking to viruses to painkillers, and collaborated with scientists around the world; he has published more than 150 articles, won awards, and served on the editorial boards of prominent journals. But in the end, all of that effort can be distilled down to one word: prevention.



Dannenberg says that more than 20 percent of cancer cases worldwide can be traced to viruses, bacteria, or parasites. 'It's quite a startling number,' he says. 'I don't think the public is sufficiently aware of the link.'

"As a physician-scientist, my goal was always to work on issues that would be of value for the general population," says Dannenberg, the Henry R. Erle, MD–Roberts Family Professor of Medicine at Weill Cornell and director of the Weill Cornell Cancer Center. "I hope that any progress I make translates to clinical benefit—and it's my belief that more emphasis should be placed on efforts to prevent cancer. That doesn't mean that I'm not devoted to developing new and improved therapies. It's just that, from a societal standpoint, I think more emphasis should be placed on preventing disease."

Over the past few years, Dannenberg has been working to spread the word about the causal relationship between infection and cancer: he says that more than 20 percent of cancer cases worldwide can be traced to viruses, bacteria, or parasites. "It's quite a startling number. I don't think the public is sufficiently aware of the link between chronic infection and cancer." With the advent of the Gardasil vaccine to protect young women from four types of human papillomavirus (HPV), Americans have become more aware of the relationship between HPV and cervical cancer. But they may not know that the same virus is closely connected to throat and oral cancer (an argument for vaccinating boys as well), that chronic hepatitis B and C can lead to liver cancer, or that *Helicobacter pylori* can cause stomach cancer.

What do those underlying conditions have in common? Inflammation, the body's response to infection. Dannenberg has become one of the world's leading authorities on the link between chronic inflammation and cancer—a relationship that he says goes far beyond the one-fifth of cancer cases caused by infectious diseases. Long-standing inflammation of virtually any tissue increases the risk of cancer, and a clearer understanding of the mechanisms underlying the inflammation-cancer connection should provide the basis for strategies to reduce cancer risk.

Dannenberg's lab has focused its efforts on a network of genes that control the synthesis (COX-2, mPGES-1) and inactivation (15-PGDH) of pro-inflammatory prostaglandins (PGs). Working with a multidisciplinary team of investigators including his longtime collaborator Kotha Subbaramaiah, PhD, the Jack Fishman Associate Professor of Cancer Prevention, Dannenberg's lab discovered that the COX-2 gene was over-expressed in a variety of premalignant and malignant conditions leading to increased levels of PGs—and that inhibiting the COX-2-PG pathway protected against the formation and growth of experimental tumors. PGs promote tumorigenesis by a number of mechanisms. For example, Dannenberg and colleagues described how the COX-2 enzyme's production of PGs increases formation of aromatase—which, as the producer of estro-

gen, plays a vital role in breast cancer.


In 2004, their work made national headlines after an article in the *Journal of the American Medical Association* reported that use of aspirin—an inhibitor of COX-derived PG synthesis—could dramatically lower the risk of developing hormone receptor-positive breast cancer, which makes up about 70 percent of cases in postmenopausal women. They began working in cell culture and confirmed their findings in a mouse model—concluding that over-expression of COX did indeed lead to an increase in aromatase. The researchers then wondered whether the findings

could be extended to women.

"The question became, how the heck would I test this idea in real time?" Dannenberg recalls. "I struggled. I did not know what to do. And then I thought to myself, I have colleagues at Columbia who have just completed this well-known breast cancer study. I knew they had collected a wealth of data concerning use of aspirin, so I went to them with a molecular hypothesis. Based on our pre-clinical studies, we hypothesized that use of aspirin, an inhibitor of PG production, might suppress aromatase levels and thereby protect against hormone receptor-positive breast cancer." Dannenberg asked the epidemiologists to interrogate their database. The findings: women who reported having ever taken aspirin showed a 26 percent reduction in hormone receptor-positive cancer, but no meaningful drop in the receptor-negative version. "As a physician-scientist, I found it gratifying," Dannenberg recalls. "Here we were demonstrating, albeit in a retrospective study, that use of aspirin, an inhibitor of pro-inflammatory PG production, led to a statistically significant reduction in hormone receptor-positive breast cancer—but it had no effect on hormone receptor-negative breast cancer, consistent with our preclinical findings."

"This work has tremendous potential for public health impact," says Clifford Hudis, MD, chief of the Breast Cancer Medical Service at Memorial Sloan-Kettering Cancer Center, a professor of medicine at Weill Cornell, and one of Dannenberg's longtime collaborators. Still, Hudis and Dannenberg stress that they don't recommend that all women take aspirin specifically for breast cancer prevention. Despite the drug's potential benefits—also protecting against heart disease—it can have serious side effects, such as stomach ulcers and brain hemorrhage. "What I can say is that for those who are taking aspirin for other reasons, there is likely to be a benefit in reducing cancer risk," Dannenberg says. He and his collaborators continue to work on the link between pro-inflammatory PGs and aromatase with the goal of developing pharmacological or dietary strategies to reduce breast cancer risk.

In a related line of investigation, Dannenberg and his collaborators are working on inflammatory bowel disease (such as Crohn's disease and ulcerative colitis), a condition that predisposes the patient to colorectal cancer. The mechanisms underlying the inflammation-cancer connection are being defined. "Many of the pathways that are aberrant in colitis are also altered in colorectal tumors," Dannenberg says. "In the short term, these mechanisms promote wound healing—but left unchecked, they lower the threshold for tumor formation." The ongoing work promises to provide new insights into the link between colonic inflammation and colorectal cancer that may result in risk reduction strategies. Another goal is to develop a personalized approach to reduce colonic inflammation.



PROVIDED BY DR. DANNENBERG


Cancer cause?: Dannenberg is investigating the role of substances released by inflammatory cells—such as these (marked by an arrow) in the breast tissue of obese mice—as promoters of cancer.

Dannenberg’s current work also includes exploring how one of America’s most pressing health issues—the fact that a third of the population is overweight and another third is obese—may also portend a rise in cancer diagnoses. “One of the things that we’re interested in pursuing now is obesity as a public health crisis,” says Dannenberg. “Most people don’t appreciate that obesity isn’t just a risk factor for diabetes or heart disease, but also for cancer.” Obese patients, he notes, are predisposed to a number of different cancers, including those of the breast, colon, endometrium, pancreas, and esophagus. “Obesity causes a sub-clinical inflammatory state,” he says. “It’s not like having a hot knee—if you have arthritis in your knee, you know about it. But in fact obesity can lead to inflammatory cells infiltrating tissues. So in addition to weight control there may be pharmacological or dietary strategies to suppress inflammation and thereby assist in reducing the personal risk of developing cancer.”

Production of PGs, he notes, is sensitive to diet—so ingesting some types of fish and other foods that contain omega-3 fatty acids could reduce PG levels and suppress inflammation. By contrast, other types of dietary fat may be pro-inflammatory. “Working in close collaboration with Louise Howe, PhD, associate research professor of cell and developmental biology at Weill Cornell, and Dr. Subbaramaiah, we are actively investigating the effects of different dietary lipids on PG levels and related inflammatory mediators in preclinical models,” says Dannenberg. “Of course, the long-term goal of this work is to be able to make evidence-based dietary recommendations. It is absolutely reasonable to believe that diets can be tailored to modify personal risk, but careful, mechanistic bench-to-bedside studies are required. It’s our view that, on a population basis, this type of work illustrates the potential of employing diet to reduce cancer risk.”

Trained as a gastroenterologist, Dannenberg earned his MD from Washington University in St. Louis and did his residency and fellowship at Weill Cornell. Although he no longer sees patients, he is every inch the physician-scientist, colleagues say. “He is a remarkable person and has amazing energy,” says Babette Weksler, MD, professor of medicine at Weill Cornell. “He organizes a complicated laboratory—people coming from all over the world, young scientists, young surgeons who often have had no background in the lab—and everyone goes away well trained and with a good paper under his or her belt. It’s a lot of different people working together and all learning a great deal. Going to his lab meeting every week is one of my pleasures.”

Both Hudis and Weksler laud Dannenberg for his skills as a collaborator, as well as for his ability to place his work into a broader context. “He is driven and passionate beyond belief—in a very good way,” Hudis says. “He’s also extremely and appropriately self-critical. When he’s presenting an idea, he’s the first person to point out if there’s something potentially wrong with it, which is the way good scientists work. I find him inspiring to collaborate with, because he works so hard, in such a tightly focused way, and pursues a specific problem to the end. When you’re with Andy, the system that his lab is focused on becomes the most important thing on Earth.” ●



An aerial night view of a city, likely New York City, showing a large river (the Hudson River) and several tall buildings with many lit windows. The sky is dark blue with some clouds. The text 'The Year in Review' is overlaid in white on the right side of the image.

The Year in Review

2008–2009



DISCOVERIES THAT MAKE A DIFFERENCE

Thank You for Partnering with Us

The *Discoveries that Make a Difference* Campaign at Weill Cornell Medical College has a singular goal: to translate our excellence in research into the most advanced treatments for patients as quickly as possible. Our physician-scientists are already in the vanguard of some of today's most profound medical discoveries, thanks to our world class position in teaching, research, and patient care, as well as our fertile collaborations across disciplines with researchers at Cornell University in Ithaca.

As of September 2009, \$865 million has been raised toward the \$1.3 billion goal for the *Discoveries* Campaign. Each gift moves us closer to our goal. We will succeed only with the continuing generosity of our alumni and friends, such as the donors whose names you see in the following pages. We are deeply grateful.

The 69th Street Medical Research Building

At the center of our *Discoveries that Make a Difference* Campaign is a new Medical Research Building, a 480,000 square-foot, sixteen-floor facility on the Weill Cornell campus. It is a close neighbor to the Weill Greenberg Center, our award-winning outpatient care facility.

The Medical Research Building heralds a new era in the landscape of Weill Cornell, doubling its current research space and fostering collaboration to promote scientific innovation. Its unique open floor plan will maximize collaboration among our renowned physician-scientists. Core facilities on each floor of the Medical Research Building will provide centralized access to state-of-the-art technology used by faculty across all research areas, increasing efficiency and reducing costs.

The Medical Research Building, a state-of-the-art blueprint for twenty-first-century science, will serve as a catalyst for pushing the boundaries of discovery to find solutions to some of our most significant health issues.

The *Discoveries that Make a Difference* Campaign will also fund additional research laboratories, scientific program development, faculty recruitment, student scholarships, and fellowships.

Key research areas include: Cancer; Cardiovascular Disease; Children's Health; Global Health and Infectious Disease; Neurodegenerative/ Neuropsychiatric Diseases and Aging; Diabetes, Metabolic Disorders, and Obesity; and Stem Cell, Developmental Biology, Reproductive, and Regenerative Medicine. To date, \$290 million has been raised toward the funding goal of \$350 million for the Medical Research Building.

The Weill Challenge

The Campaign received a significant boost when Joan and Sanford I. Weill established the *Weill Challenge*, a program that offers matching funds for gifts to the Medical Research Building. The *Weill Challenge* will allow more donors to maximize the impact of their gifts: every \$1.50 given to the Research Building will be matched with \$1.00 from Mr. and Mrs. Weill. The *Weill Challenge* has been launched at a critical time, when so many of the Medical College's supporters are feeling the effects of the economic downturn.

This is a historic moment in scientific discovery. With your support, this groundbreaking Campaign will leverage the world-class expertise of our faculty and propel next-generation breakthroughs in prevention, treatment, and cures for some of our most debilitating and urgent health conditions. Thank you for joining us.

We are grateful to all the generous friends who have supported Weill Cornell over the past year. Special thanks are extended to the following donors whose gifts of \$1,000 or more were recorded during the fiscal year July 1, 2008, through June 30, 2009:

AAF/Salzburg Cornell Seminars	Philip Auerbach	Jerry Blickman, Inc.	CapFinancial Partners, LLC
Michael Aaron	Dr. William S. Augerson	Michele Blickman	Dr. Michael E. Carey
Aaronson Rappaport Feinstein & Deutsch LLP	The Auxiliary of NewYork-Presbyterian Hospital	Blinken Foundation, Inc.	Gerald Carlin Revocable Trust
Robert H. Abrams	Avellino Family Foundation	BLL Foundation	Dr. Roland D. Carlson
Hugh Trumbull Adams	Avon Products, Inc.	Edith C. Blum Foundation, Inc.	Peter W. Carmel, MD
Dr. Dale Steven Adler	Janet Axelrod	Mr. and Mrs. Donald J. Blum	Dr. and Mrs. John J. Caronna
The Adler Family Foundation, Inc.	The B.R.A.I.N. Foundation	Dr. Samantha V. Boardman and Aby Rosen	The Carson Family Charitable Trust
Advanced Bionics Corporation	The Bachmann Strauss Dystonia & Parkinson Foundation, Inc.	Mary Bocage	Stephen H. Case
Advanced Neuromodulation Systems, Inc.	Fady Baddoura	Boehringer Ingelheim Fonds	Frank Casillo
Advanced Research Foundation, Inc.	Mrs. Frederick Bailey	Boehringer Ingelheim Pharmaceuticals, Inc.	Philip Castellano
Affiliated Computer Services, Inc.	Felicie R. Balay	Alice Bohmfalk Charitable Trust	John K. Castle
Ahepa Fifth District Cancer Research Foundation	Sallie Baldwin	Dr. Jeffrey S. Borer	Castle Harlan
Dr. Michael M. Alexiades	Ballinger	Unn J. Boucher	Catholic Communal Fund
Alexico Group	The Bandier Family Foundation	Bovis Lend Lease LMB, Inc.	Miriam Goldman Cedarbaum
Dr. Patricia Yarberry Allen	The Bank of New York Mellon Community Partnership	BPD Bank	Center for Cancer Prevention Research, Inc.
Mrs. Herbert Allen Sr.	Dr. Jack D. Barchas and Dr. Rosemary A. Stevens	Brant Industries, Inc.	Central Parking Corporation
Allergan Pharmaceuticals, Inc.	Bariatric Advantage	Dr. Eric R. Braverman	Yee Min Chan
AllianceBernstein	Doris W. Barth	The Braverman Group, Inc.	Jayne K. Chandler
Mr. and Mrs. David Almeida	Albert Baum	William J. Bresnan	Chanel, Inc.
Dr. Katharine S. Almy	Steven Baum	Dr. Harold T. Brew Jr.	Mr. and Mrs. Alexander E. Chapro
Altman/Kazickas Foundation	Baxter Healthcare Corporation	Leslie Simmons Brille	The Charina Endowment Fund, Inc.
Dr. and Mrs. Ellsworth C. Alvord Jr.	Bear Stearns Securities Corp.	Bristol-Myers Squibb Company	Charina Foundation
Martin B. Amdur	Becton Dickinson and Company	T. J. Bristow	Mr. and Mrs. David H. Chase
Randolph Amengual	Jessica I. Bede	British Journal of Anaesthesia	Dr. Frank A. Chervenak
American Biltrite	The Arthur and Rochelle Belfer Foundation	Dr. and Mrs. Jack M. Bromley	Chez Renee
American Society for Metabolic & Bariatric Surgery	The Robert A. and Renee E. Belfer Family Foundation	Brookfield Financial Properties, LP	Mordechai Chetrit
Amethyst, LLC	Benhar Office Interiors	Katherine Brosnahan	Children's Blood and Cancer Foundation
Amgen	Ray M. Bennett	Christopher C. Brown	Denise A. & Eugene W. Chinery Foundation, Inc.
Mr. and Mrs. Mahyar Amirsaleh	Norman S. Benzaquen	Dr. Harry G. Browne	David Chou
Asokan Anandarajan	Mr. and Mrs. James Berezny	Nancy D. Browne	Henry Christensen III
Anchor Capital Advisors	Philip J. Bergan	Dr. Francis E. Browning	Theodore C. Chu
Dr. Holly S. Andersen	Christine Berger	Bryan Cave, LLP	Jean Cinelli, JD
Mr. and Mrs. K. Tucker Andersen	Rosalind & Alfred Berger Foundation	Dr. J. Robert Buchanan	Mary Cirillo-Goldberg
Jay Anderson	Irene Bergman	Dr. Joseph A. Buda	Citi Global Impact Funding Trust, Inc.
Linn Anderson	Louis and Sandra Berkman Foundation	Dr. Robert L. Buly	Mr. and Mrs. Peter Claman
The Honorable and Mrs. Hushang Ansary	Berkshire Taconic Community Foundation	Florence V. Burden Foundation	Estate of Edith Allen Clark
Dr. Madelyn Antonic	Madaleine Berley	Mr. and Mrs. Daniel B. Burke	James McConnell Clark
Aon Foundation	Madeleine H. & Mandell L. Berman Family Support Foundation	Kathleen M. Burke	Virginia Clark Clarkson
Apatech	Bernstein Family Fund	Peter M. Burkholder, MD '59	Dr. John A. Clements
Helen J. Appel	I. Jack and Elsie L. Bernstein Foundation	Mr. and Mrs. Jack D. Burks	Chris and Pam Cloud
Robert J. Appel	Beryl Companies	John Dexter Bush Trust	The Coats Family Foundation
Dr. George A. Arangio	Aurora L. Biamonte	Business of Entertainment Inc.	Coeur D'Arlene Mines
George and Judith Arangio Foundation	Jessica M. Bibliowicz	Dr. Lili R. Bussel	Dr. and Mrs. David A. Cofrin
Adrian & Jessie Archbold Charitable Trust	Biogen Idec	Lili R. Bussel Charitable Lead Annuity Trust	Mr. and Mrs. Edwin A. Cohen
Sanji Arisawa	Mr. and Mrs. Sherwood C. Blake	Buster Foundation	Mr. and Mrs. Harvey W. Cohen
Armour-Lewis Family Foundation	Elizabeth Blaney	The Edward H. Butler Foundation	Irving Cohen
Aronson Family Foundation	Nancy & Robert S. Blank Foundation	Charles C. Cahn Jr.	Mr. and Mrs. Lawrence Cohen
Yvonne Uran Arthur	Dr. James C. Blankenship	Caldwell & Walsh Building Construction	Richard P. Cohen, MD
Ascend Capital	The Lloyd and Laura Blankfein Foundation	Mr. and Mrs. Robert A. Calinoff	Rita F. Cohen
The Ashken Family Foundation	Dorothea Blatt Revocable Trust	Lynn R. Callagy	Steven N. Cohen, MD '74
Asubio Pharma Research	Arnhold and S. Bleichroeder Advisers, Inc.	David J. Callans	The Abby and David Cohen Family Foundation
Dr. Robert C. Atkins Foundation		Dr. Stefano Camici	Friends of Jon Cohen
Atlantic		Mr. and Mrs. John D. Campbell	Steven A. and Alexandra M. Cohen Foundation, Inc.
The Atlantic Philanthropies (USA) Inc.		Cancer Research and Treatment Fund, Inc.	The Jacques & Emy Cohenca Foundation
The Atlas Heritage Foundation		Cangene Corporation	
		Pamela Cantor, MD '81	
		Cantor Foundation	

Dr. Symra A. Cohn
 Dr. Curtis L. Cole
 Charles P. Coleman III
 The Coleman Foundation
 The Chase and Stephanie Coleman Foundation
 Dr. Pamela Y. Collins
 Alan Colner
 Community Counselling Service Co., Inc.
 Community Foundation of New Jersey
 Community West Foundation
 Concannon Family Foundation
 Mr. and Mrs. Andrew Connelly
 Dr. Michael M. Conroy
 Mr. and Mrs. Robert S. Constable
 Mr. and Mrs. Harry C. Cook
 Jonathan Cook
 Mr. and Mrs. Marc Cooper
 Richard B. Cooper
 Dr. Gerald J. Cordani
 The Corey Foundation
 Dr. Charles N. Cornell
 Mr. and Mrs. Marc B. Cornstein
 Mr. and Mrs. Robert J. Corti
 Covidien
 Howard E. Cox
 Cox Foundation
 Cross Country Travcorps, Inc.
 John F. Crowe, MD '71
 Lewis B. and Dorothy Cullman Foundation, Inc.
 Dr. Victor T. Curtin
 Filomen M. D'Agostino Foundation Corp.
 Frances C. Dalessandro
 Dr. Frederic G. Dalldorf
 Iris G. Damson
 Norma Dana
 Dancers Care Foundation, Inc.
 D. Ronald Daniel
 Delphine Daniels
 Dark Starr Advisors, LLC
 Mr. and Mrs. Norris Darrell Jr.
 Datawatch Corporation
 Jack David
 Agathe M. David-Weill
 Mr. and Mrs. Michel David-Weill
 Davies/Weeden Fund
 Mr. and Mrs. Douglas R. Dayne
 Yves De Balmann
 Mrs. Vincent de Roulet
 Mr. and Mrs. Remy P. De Varenne Jr.
 William D. Dearstyne Charitable Lead Annuity Trust
 Dr. John Deitrick
 Audrey Zauderer del Rosario
 Mr. and Mrs. John D. Delafield
 Mr. and Mrs. Richard Dennett
 Dennett Law Offices, PC
 John DeRuzza
 Elsa P. Desrochers
 DeWitt Rehabilitation and Nursing Center
 Estate of Rosalind A. Diefenderfer
 Mr. and Mrs. C. Douglas Dillon
 Joe and Diane DiMenna
 Joyce Dinkins
 Francis C. Divisek Charitable Lead Trust
 Gail S. Dobosh

James F. Dolan
 Jerome and Laura Dorfman Charitable Foundation
 Erica A. Drake Trust
 Dr. Michael R. Drews
 Jean & Louis Dreyfus Foundation
 The Drukier Foundation, Inc.
 Estate of Georgianna Ducas
 Lynn A. Ducommun
 James H. Duffy
 Dr. Francis J. Duggan Jr.
 Sharon Z. Duggan
 Michael F. Duke
 Elizabeth J. Dunn
 Mrs. Walter G. Dunnington
 Susan Dusenberry
 Dworman Foundation
 Dyson Foundation
 Margaret M. Dyson Trust
 Eagan Family Foundation, Inc.
 East River Medical Imaging
 East Sea Shipping Co. Ltd.
 Mr. and Mrs. Kenneth Eberts
 Linda Edelman
 Edelman Foundation
 Mr. and Mrs. Maurits E. Edersheim
 Edgewood Holdings, LLC
 Sally Matson Edwards
 Edythe Griffinger Trust
 EF Communications, LLC
 Mr. and Mrs. Sanford B. Ehrenkranz
 The Daniel J. and Edith Ehrlich Family Foundation
 Dr. Eli Einbinder
 Margaery A. Einstein
 Dr. Howard M. Eisenberg
 Marvin and Barbara Eisenstadt Charitable Foundation
 Elberon Development Company
 Marjorie Ellenbogen
 Per E. Ellingsen Revocable Trust
 Estate of Robert Ellman
 Mrs. Jerry Elsner
 Mr. and Mrs. Howard Emery
 Constance Emmerich
 Linda Rodgers Emory
 Endo Pharmaceuticals
 The Robert G. and Jane V. Engel Foundation, Inc.
 Mr. and Mrs. Robert Englander
 Englander Foundation, Inc.
 Enterprise Foundation
 Epilepsy Foundation
 Epimed International, Inc.
 Epstein, Becker & Green, PC
 Eroica Music, Inc.
 Ethicon Endo-Surgery, Inc.
 Dr. Stephen E. Ettinghausen
 The Charles Evans Foundation
 Execution, LLC
 ExxonMobil Foundation
 F. Hoffman-La Roche, AG
 Dr. and Mrs. Thomas J. Fahey Jr.
 Carmine Falcone
 Gay A. Fallows
 Tania Fano
 Moufid Farra
 Nancy L. Farrell
 FC Yonkers Associates

Facts and Figures

from Weill Cornell Medical College and the Graduate School of Medical Sciences

Entering medical students

Total applications received	5,577
Male	2,953
Female	2,624
Under-represented minorities	679
Total applicants interviewed	732
Total acceptance letters sent	290

Matriculating students (Fall 2009)	101
Male	55
Female	46
Under-represented minorities	25
New York State residents	33
Out-of-state residents	66
International students	2
Age range in years	20–36
Average age	23.6

Average science GPA	3.73
Cumulative GPA	3.75
Average MCAT score	11.5
Verbal	10.6
Physical science	11.7
Biological science	12.1

Entering PhD students

Matriculating students (Fall 2009)	40
Male	10
Female	30
Under-represented minorities	8
New York State residents	7
Out-of-state residents	19
International students	14

Average science GPA	3.6
Average GRE scores (percentiles)	82.5 %
Verbal	82 %
Quantitative	83 %

Tri-Institutional MD-PhD Program

Matriculating students (Fall 2009)	14
------------------------------------	----

Total enrolled students

Medical students	363
Graduate students	545 *
MD-PhD students	43

*Includes: 352 PhD; 20 PhD Tri-I Chemical Bio; 18 PhD Tri-I Computational Bio; 20 MS Clinical Epidemiology; 36 MS Clinical Investigation; 99 MS Physician Assistant

Degrees conferred (May 2009)

MD	92
PhD	58
MS	17
MD-PhD	13

Marilyn and Michael Fedak
 J. Peter Fegen, MD '63
 The Feil Family Foundation
 Louis Feil Charitable Trust
 Louis Feinberg Foundation
 Herbert Feinberg
 Felberbaum Family Foundation
 Mr. and Mrs. William Felder
 Diana Feldman
 Ronald Feldman Fine Arts, Inc.
 Mr. and Mrs. Laurence T. Fell
 Elizabeth A. Fell
 Dr. Frederick J. Ferlic
 E. Robert Fernholz
 Massimo and Chiara Ferragamo
 Geraldine Ferraro
 Jerald Fessenden
 Marlene B. Feuerring
 Fidelity Charitable Gift Fund
 Mr. and Mrs. William
 Filonuk Jr.
 Dr. Joseph Finkelstein
 D. F. K. Finlay
 Linda Fish, Esq.
 Susan J. Fishburn
 Dr. Jeffrey D. Fisher
 Irene S. Fisher and Barry L. Fisher
 Charitable Trust
 Mr. and Mrs. Arthur Fleischer Jr.
 Mr. and Mrs. Nelson Fleishman
 Mr. and Mrs. Mark Fleming
 Samuel C. Fleming
 Flower Hill Auto Body, Inc.
 Dr. Kathleen M. Foley
 Dr. Raymond Fong
 Barbara Fontana
 Anne Ford
 Charlotte M. Ford
 The Gerald J. Ford Family Foundation
 The Henry Ford II Fund
 Rhoda Forman
 Foster Davis Foundation, Inc.
 Estate of Jane M. G. Foster
 Dr. Howard and Ms. Barbara Fox
 Dr. David G. Fraser
 Millicent Freedman
 Solomon & Edith Freedman
 Charitable Foundation
 Estate of Muriel Freeman
 Mr. and Mrs. Sanford Freiman
 Mr. and Mrs. John H. French II
 The Joseph L. and Ray L. Freund
 Foundation
 The Fried Foundation
 Barbara Friedberg
 Robert J. Friedlander
 Friedman Family Foundation
 Barbara and Stephen Friedman
 Ruth W. Friendly
 Mr. and Mrs. Matthew M. Friestedt
 Sandra G. Frisoli
 The L.W. Frohlich Charitable Trust
 David Fromkin
 Fross Zelnick Lehrman & Zissu PC
 Charles A. Frueauff Foundation, Inc.
 Fund for Blood and Cancer Research
 William H. Furth
 Michael Gagarin
 Gagosian Gallery, Inc.
 Jill Gallagher
 Andrew J. Galligan Jr.

Francis W. Gamache Jr., MD
 Garfunkel, Wild & Travis, PC
 Mr. and Mrs. Joseph Garoppolo
 The Garrett B. Smith Foundation
 Joyce Garson
 Seymour Gartenberg
 Elizabeth W. Gates
 GE Capital
 Melvin Gebroe
 Michele Geller
 Rosa and Robert Gellert
 Genentech, Inc.
 Mr. and Mrs. Michael Generoso
 Genesis Flooring Systems, LLC
 The Georgescu Family Foundation
 William T. Georgis
 Edithann M. Gerard
 Dr. Arthur M. Gerber
 Gail U. Geronemus
 GI Dynamics, Inc.
 Dr. and Mrs. Gary E. Gibson
 Gilead Sciences, Inc.
 S. Hazard Gillespie
 Estate of Thelma Gish
 The Benjamin Gittlin Foundation
 Givingexpress Online from American
 Express
 Walter W. Glaeser Trust
 GlaxoSmithKline
 Glaxosmithkline Foundation
 Gertrude Glekel
 Estate of Helena L. Glover
 Goerlich Family Foundation, Inc.
 Dr. Jeffrey P. Gold
 Michael B. Goldberg
 Seth J. Goldfarb
 Goldman Sachs & Co.
 Goldman Sachs Group
 Goldman Sachs Philanthropy Fund
 Jay S. Goldsmith
 Elliot Goldstein, MD
 Dr. Jonathan V. Goldstein
 Dr. Marc Goldstein
 Peter Goldstein
 Sidney Goldstein, MD
 N. S. Goldstein Foundation, Inc.
 Mr. and Mrs. Peter Goltra
 David Golub
 The Mildred B. and Philip P. Goodkin
 Family Foundation, Inc.
 W. L. Gore & Associates, Inc.
 Joseph L. Gossner
 Mr. and Mrs. Harry E. Gould Jr.
 The Florence Gould Foundation
 Matthew Grabowsky
 Oliver R. Grace Charitable Foundation
 Dr. Bernice S. Grafstein
 Camille E. Granato
 The Granet Foundation
 Dr. Richard D. Granstein
 Dr. Robert T. Grant
 Grayson Fund
 Dr. Joseph Grayzel
 The Greater Cincinnati Foundation
 Greater New York Hospital Association
 George J. Green
 Beatrice W. Greenbaum
 Theodora S. Greenbaum
 Joel I. Greenberg
 Maurice R. and Corinne P. Greenberg
 Philip Greer

Greer Family Foundation
 Mr. and Mrs. Peter S. Gregory
 Dr. Christopher E. Gribbin
 John and Amy Griffitt Foundation
 Peter J. Grillo, MD
 The Lola B. Grillo Foundation
 The Griswold Company, Inc.
 Mr. and Mrs. Michael Groll
 The Julia and Seymour Gross
 Foundation
 L. Jay Grossman
 Ronald Grossman
 Mr. and Mrs. Sanford S.
 Grossman
 Group J Inc.
 The Grove Creek Fund
 The Gruson Fund for Brain Tumor
 Research
 Mr. and Mrs. Joshua Gruss
 Gruss-Lipper Family Foundation
 Dr. Lorraine J. Gudas
 Dr. Peter M. Guida
 Aaron & Marion Gural
 Foundation
 Jeffrey Gural
 Mr. and Mrs. Philip H. Gutin
 Cary L. Guy Foundation, Inc.
 Mr. and Mrs. William H. Hadley
 Mr. and Mrs. James J. Hagan
 Hagedorn Fund
 Peter and Helen Haje
 Mr. and Mrs. Frederic C.
 Hamilton
 Mr. and Mrs. Norman Hammer
 Hammerschlag Family
 Foundation
 Hand Surgery Associates of NY,
 PC
 Jerry S. Handler
 The Handler Foundation
 Jose K. Harfush
 Mr. and Mrs. Leonard M. Harlan
 Harmil Foundation
 Gladys and Roland Harriman
 Foundation
 Mary W. Harriman Foundation
 Harris Bankcorp, Inc.
 Eva Hartman
 Cynthia A. Hartog
 The Hartwell Foundation
 The Ellen B. Harvey Foundation,
 Inc.
 Anne Hayworth
 Dr. Robin S. Hayworth
 HDR Architecture, Inc.
 John H. Healey, MD
 Health Resources Optimization,
 Inc.
 Mr. and Mrs. Andrew Heaney
 Mr. and Mrs. Peter Hearst
 The William Randolph Hearst
 Foundation
 Mr. and Mrs. Bruce J. Hector
 Heiferman Family Foundation
 Rose T. Heim
 Dr. George F. Heinrich
 Heisman Trophy Trust
 Mr. and Mrs. Herbert Heller
 Mr. and Mrs. Michael Heller
 Alec Hemer
 Jung Heon

The Hermione Foundation
 John S. Herold
 Raymond R. Herrmann Jr.
 Dr. Edmund M. Herrold
 Barbara Hershman
 Hertog Foundation
 Hess Companies
 Annette Heyman Foundation,
 Inc.
 Gregory P. Heyman
 Hickory Foundation
 Hickrill Foundation
 Robert G. Higgins
 The Hilson Fund, Inc.
 Dr. William V. Hindle
 Dr. William H. Hines
 Ruth Hirsch
 Irma T. Hirschl Trust
 Margaret M. Hitchcock Fund
 Jacqueline Harris Hochberg
 Foundation
 Virginia D. Hoeffler
 Lisa Hofer
 Diane S. Hoff
 Dr. Stephen L. Hoffman
 The Nancy and John Hoffmann
 Foundation
 HOK Inc.
 Marjorie H. Holden
 John W. Holman Jr.
 Mr. and Mrs. Leonard Holtz
 Benjamin H. Homan Jr.
 Charitable Trust
 Home Office
 Honeywell Hometown Solutions
 Dr. Susannah K. Horger
 Andrea Horowitz
 Ann & Joel Horowitz Family
 Foundation
 The Hospital for Special Surgery
 Shirley Howe
 Mr. and Mrs. Henry H. Hoyt Jr.
 Suzanne C. Hoyt
 The Hoyt Foundation
 Hub International Northeast
 Limited
 Dr. Robert J. Hubsmit
 Hudson News Distributors
 H. M. Hughes Co., Inc.
 Mr. and Mrs. Frank H. Hughes
 Estate of Theresa Humphreyville
 Estate of Adeline B. Hunold
 Mrs. Gregg Hymowitz
 The Hymowitz Family Foundation
 IBEC Building Corporation
 I-Flow Corporation
 IgG of America, Inc.
 Imclone Systems Inc.
 Infinite Possibilities Foundation,
 Inc.
 Inserra Supermarkets, Inc.
 Intellidot Corporation
 Interior Move Consultants, Inc.
 International Society for
 Computerized Electrocardiology
 IntraMed
 Iroquois Avenue Foundation
 Mr. and Mrs. Kenneth Iscol
 The Iscol Family Foundation, Inc.
 Thomas C. Israel
 J.T.K. Foundation

Arlene Jacobi
 Joseph M. Jacobs
 Dr. Michael I. Jacobs
 Mr. and Mrs. Robert A. Jacobs
 Carl Jacobs Foundation
 The Melvin and Rosalind Jacobs
 Family Foundation
 The Stanley R. & Elisabeth G. Jacobs
 Foundation
 Kathy and Mitchell Jacobson
 John H. Jacobus
 Mr. and Mrs. Mark A. Jaffe
 Dr. Anand S. Jagannath
 Michael Jaharis
 James Family Charitable Foundation
 Janklow Foundation
 Jaros Baum & Bolles
 JBRH Advertising & Design Inc.
 The Jewish Communal Fund
 JFK Medical Staff, Inc.
 JGD Management Corp.
 Mr. and Mrs. Niels W. Johnsen
 Mr. and Mrs. Charles B. Johnson
 Johnson & Johnson Corporate
 Johnson & Johnson Services
 Mr. and Mrs. Marvin Josephson
 Sally Jules
 Dr. Neil Louis Julie
 Mr. and Mrs. Peter S. Kalikow
 Jerald Kamiel
 Kanas Family Foundation
 Kandell Fund
 Annette Kaplan
 Mr. and Mrs. Barry A. Kaplan
 Dr. Gustav Edward Kappler III
 Krishan Kapur
 Jerold Katz
 Mr. and Mrs. Neil Katz
 Dr. Dick Katzin
 Dr. Bruce D. Kaufman
 George S. Kaufman
 The Kaufman Foundation
 The Harvey & Gloria Kaylie
 Foundation, Inc.
 William H. Kearns Foundation
 Lilli Keene
 Gershon Kekst
 Keller, O'Reilly & Watson, PC
 Mr. and Mrs. James P. Kelly Jr.
 Kelso & Company
 Mr. and Mrs. Finbar Kenny
 Constantine Keremet
 Patricia F. Keresztes
 Dr. Martin E. Kessler
 Bennett A. Killmer
 Mr. and Mrs. Charles Kime
 Nils A. Kindwall
 The Jena & Michael King Foundation
 Mr. and Mrs. Harold J. Kingsberg
 Richard N. Kirshenbaum
 Kitware, Inc.
 Carol L. Klapper
 Phyllis and Harvey Klein, MD
 Andrea Klepetar-Fallak
 Mr. and Mrs. Bernard Klevan
 Dr. William C. Klingensmith III
 Mr. and Mrs. Steven B. Klinsky
 Louis & Rose Klosk Fund
 Samuel Aba and Sisel Klurman
 Foundation
 Knoll
 Mr. and Mrs. David H. Koch
 William I. Koch
 Mr. and Mrs. Immanuel Kohn
 Kenneth K. Kolker
 The Kenneth Kolker Foundation, Inc.
 Mr. and Mrs. Charles E. Koob
 Lewis and Sharon Korman
 Foundation
 Mr. and Mrs. David L. Kornblau
 Jules and Helen Kornblau
 Mr. and Mrs. Kenneth Kornblau
 Mrs. Burton L. Kossoff
 William K. Kramer & Naomi Kramer
 Charitable Remainder Trust
 Dr. Nathan Kravis
 Stewart H. Krentzman
 Dr. Kenneth J. Kress
 Gerd L. Kristeller
 Alice L. Kulick Foundation
 Mr. and Mrs. Thomas P. Kurlak
 Stuart Kurlander
 John E. and Elizabeth Kurtz
 Charitable Foundation
 Mr. and Mrs. Nat Kurtz
 Gerhard E. Kurz
 L.I.S.Z. Foundation
 Renato V. LaRocca, MD
 Patricia Labranche
 Dr. Elisabeth A. Lachmann
 Thomas M. Lamberti
 Stephanie Landess
 Landor Associates
 Todd Langer
 Estate of Milton Lanz
 Dr. Frank J. Lanza
 Patricia Lanza
 William and Mildred Lasdon
 Foundation
 Latham & Watkins LLP
 Estee Lauder, Inc.
 Lauder Foundation
 Dr. Edith A. Laufer
 Leonard Lauren
 Marguerite M. & Carl G. Lautenbach
 Trust
 Dr. and Mrs. Michael H. Lavyne
 William F. Lawrence
 Lawrence Hospital
 Cynthia Leary
 Dr. Diane B. Lebowitz
 Lederman Family Foundation
 Charles R. Lee
 James W. Lee, MD '83
 The Lee Family Foundation, Inc.
 Mr. and Mrs. Ira F. Leeds
 Isabelle Leeds
 Joseph and Juanita Leff Charitable
 Trust
 Richard S. and Karen Lefrak
 Charitable Foundation, Inc.
 Samuel J. & Ethel Lefrak Charitable
 Foundation
 The Lehman Brothers Foundation
 Lehman Brothers, Inc.
 Phyllis Leibowitz
 Robert L. Lenzner
 The Leon Levy Foundation
 Dr. George S. Lerman
 Dr. Toni Lerut
 Estate of Elise Strang L'Esperance
 David Levidow
 Lawrence J. Levine
 Mr. and Mrs. Jerome Levinson
 Stephanie Levitt
 Lexington Neurology Associates, PC
 Dr. Charles E. Libby
 Mark Lichter
 Dr. Jacob Lichy
 Ligand Pharmaceuticals
 Eli Lilly and Company
 Linton Foundation, Inc.
 Littler Mendelson Foundation, Inc.
 Harold Litvak, DMD
 The Litwin Foundation
 Bruce Llewellyn
 Victoria Loconsolo Foundation, Inc.
 Logos in Print
 Iris L. Long
 Mr. and Mrs. Michael G. Long
 Longhill Charitable Foundation
 Dr. John N. Loomis
 Claire S. Lord
 Giovanni Lorenzini Medical
 Foundation
 Anthony Loschiavo
 Dr. and Mrs. Gerald Loughlin
 James D. Lowe
 Mr. and Mrs. George T. Lowy
 Lowy & Donnanth
 Walter J. Luby III
 Estate of Dr. Milton N. Luria
 Helen and Rita Lurie Foundation
 Caroline Lussi
 Luxury Jewelers Resource Group, LLC
 Mr. and Mrs. John Lykouretzos
 The Lymphoma Foundation
 Caroline H. Lynch
 Richard Lynch
 Susan E. Lynch
 Ronald P. and Susan E. Lynch
 Foundation
 Hazel M. Lyon
 M.Y.B. Foundation
 Nigel S. MacEwan
 Christy and John Mack Foundation
 Josiah Macy Jr. Foundation
 Kim Maffei
 Joseph M. Mandel
 Lewis R. Mandel
 Karl G. Mangold, MD
 Myrna A. Manners
 Mr. and Mrs. Burt Manning
 Lynn Manning
 Amir & Rosita Manocherian Family
 Foundation
 Mr. and Mrs. Frank L. Mansell
 Max and Pearl Ann Marco Family
 Foundation
 Mariner Investment Group
 Mr. and Mrs. Morris Mark
 Lois B. Marks
 Carl Marks & Co., LP
 MARMA Foundation
 Joe and Pasena Maroun Family
 Foundation Trust
 John L. Marquardt, MD '67
 Dr. Sumner Marshall
 Gloria S. Marti
 Martin, Clearwater & Bell
 Joanne E. Masin
 Michael T. Masin
 Mr. and Mrs. George Matelich
 Matrix Mechanical Corp.
 Mr. and Mrs. Edward E.
 Matthews
 Abby Rockefeller Mauze
 Charitable Trust
 Millicent N. May
 Mr. and Mrs. Christopher Mayer
 Mr. and Mrs. Richard Mayer
 McAloon & Friedman
 Sean M. McAuley
 Mr. and Mrs. Joseph F. McCann
 Mark J. McCooley
 Mr. and Mrs. Robert H. McCooley
 Jr.
 McDermott Will & Emery
 Charitable Foundation
 Julia A. McGee
 Mr. and Mrs. John F.
 McGillicuddy
 Dr. Thomas P. McGovern
 William McKeown
 McLaughlin & Stern, LLP
 Mr. and Mrs. Gary McLoughlin
 McMahan Publishing Group
 Dr. Allen W. Mead
 Meckler Foundation, Inc.
 Dudley C. Mecum
 Media Cares Foundation
 The Peter C. Meinig Revocable
 Trust
 Yvonne C. Meinwald
 Karen Meister
 Mr. and Mrs. Robert Meister
 Vittoria Menashe
 Paul R. Mendelsohn
 Susan Mendik
 Robert and Joyce Menschel
 Family Foundation
 Merck & Co.
 Mercury Ring
 Erwin Mermelstein, MD
 The Merow Foundation
 Mr. and Mrs. Ricardo A. Mestres
 Jr.
 Helen N. Mettler
 Mr. and Mrs. George A. Metzger
 Lewis H. Meyers
 Dr. Fabrizio Michelassi
 Microsoft Corporation
 Alan B. Middleton
 Milbank Memorial Fund
 Milberg Factors, Inc.
 Dr. Carlyle H. Miller
 Dr. Dinah Miller
 Miller & Milone
 Jennifer L. Millstone
 Mr. and Mrs. Howard P. Milstein
 Mr. and Mrs. Manish Mittal
 Miura Global Management, LLC
 Monkey Productions, Inc.
 Harry Montero Trust
 Mr. and Mrs. Richard W. Moore Jr.
 James A. Morakis
 JPMorgan Chase
 Morgan Construction Enterprises,
 Inc.
 Mr. and Mrs. Edwin H. Morgens
 Mr. and Mrs. John L. Morris
 The Morse Family Foundation,
 Inc.
 Mount Olive Baptist Church

Multiple Sclerosis Foundation
 Munn Rabot, LLC
 Mr. and Mrs. Edward Munves Jr.
 Donald B. Murphy
 Bernadette E. Murray
 Mr. and Mrs. Robert C. Myers
 Maithily A. Nandedkar-Thomas, MD '99
 Mr. and Mrs. Howard A. Nanes
 Helen S. Nathan
 Edward Nathanson
 National Philanthropic Trust
 Benjamin Navarro
 Mr. and Mrs. Don H. Nelson
 Mr. and Mrs. Richard Neuberger
 Roy R. and Marie S. Neuberger Foundation, Inc.
 Neurologix, Inc.
 NeuroTherm, Inc.
 The New York Community Hospital of Brooklyn, Inc.
 The New York Community Trust
 New York Crohn's Foundation
 New York Downtown Hospital
 New York Firefighters Burn Center Foundation
 The New York Gracie Square Hospital
 The New York Hospital Medical Center of Queens
 New York Methodist Hospital
 New York Urological Associates, PC
 New York Westchester Square Medical Center
 Robert and Ann Newburger Foundation, Inc.
 Steven O. Newhouse
 Samuel I. Newhouse Foundation
 Newman Tanner Foundation
 The Arthur and Eileen Newman Family Foundation
 Newman's Own Foundation
 June Newmark
 The News Corporation Foundation
 Clifford G. Newton
 NGM Biopharmaceuticals, Inc.
 Susanne R. Nichol
 1923 Fund
 Nixon Peabody, LLP
 David P. Nolan Foundation, Inc.
 Not Your Ordinary Dancers, Inc.
 Dr. Eugene John Nowak
 Dr. Judith A. Nowak
 NY Neuroscience Associate, PC
 Dr. and Mrs. William O'Bell
 William O'Connor
 Ogilvy & Mather
 Dr. Peter M. Okin
 The Olian Foundation, Inc.
 Olympus
 Mr. and Mrs. Stanley O'Neal
 The Optima Fund Management, LLC
 Jeanne A. O'Reilly
 Orentreich Family Foundation
 OR-Live, Inc.
 Mrs. William H. Osborn Jr.
 Richard D. Osborne
 Osceola Foundation, Inc.
 Dr. Gerald C. O'Sullivan
 The Outsource Group Medcredit, Inc.
 Mr. and Mrs. Daniel P. Paduano
 Pain Management Symposium
 Hannah Pakula
 Daniel R. Paladino
 Jeffrey Paley
 Estate of Narain Panjwani
 Aaron D. Panker
 Dr. Gideon G. Panter
 Panter Foundation
 Mr. and Mrs. Jordan Pantzer
 Mr. and Mrs. James Papianni
 Mr. and Mrs. Milton J. Pappas
 Dr. Herbert Pardes
 Park Avenue Charitable Fund
 Partners HealthCare Systems, Inc.
 The Robert J. and Claire Pasarow Foundation
 Dr. Mark W. Pasmantier
 Jorge Pasquel
 Russel H. Patterson Jr., MD '52
 The Andrew M. Paul Family Foundation
 Joanne D. Payson
 Dr. Paul M. Pellicci
 Dr. Ole A. Peloso
 Mr. and Mrs. Nelson Peltz
 Pentax of America, Inc.
 Edward A. Perell
 The Perelman Family Foundation
 Performance Orthopedics of the Palm Beaches
 The Perkin Fund
 Mr. and Mrs. Joel Perlmutter
 Mr. and Mrs. Richard Perry
 The Pershing Square Foundation
 Elizabeth Peters
 The Alton E. Peters Charitable Trust
 Susan Petschek
 The Pevaroff Cohn Family Foundation
 Pfizer Inc.
 PHF Foundation
 Dr. Lisa A. Piazza
 Picket Family Foundation, Inc.
 The Picower Foundation
 Luke Pittoni
 Place for Achieving Total Health Medical, PC
 Melvin R. Platt
 Bruce Polozker
 Polshek Partnership Architects
 Mr. and Mrs. McGehee L. Porter III
 Edward K. Portnof
 Poses Family Foundation
 Dr. Jerome B. Posner
 Patricia Posner
 Joan and Dennis Poster
 Michael R. Potack
 Premier & Company
 Gladys P. Preston
 Peggy Wolff and Chuck Prince
 Dr. R. A. Rees Pritchett
 Margot and Thomas Pritzker Family Foundation
 Dr. Alan D. Proia
 Prostate Cancer Foundation
 Jennifer Protas
 Psychists Inc.
 Mr. and Mrs. Dennis Purcell
 Dr. Donald O. Quest
 John A. Quisenberry
 R & J Components Corporation
 Marcia Raff
 Michael and Paula Rantz Foundation
 Norman P. Rappaport Foundation
 Mr. and Mrs. Robert J. Ravitz
 Dr. Lawrence W. Raymond
 Clara Redline Trust
 Edgar Reeve
 Seymour Reich
 The Reiss Family Foundation
 Renaissance Charitable Foundation
 Dr. Gene D. Resnick
 The Burton P. and Judith B. Resnick Foundation
 Eleanor Ressler
 Retina Research Foundation
 Charles H. Revson Foundation
 James P. Rhodes, MD '60
 Mr. and Mrs. Frank H. T. Rhodes
 Dr. Jack Richard
 Henry and Ida Richard Foundation
 Mr. and Mrs. Reuben F. Richards
 Ronald N. Riner, MD
 The Riner Group, Inc.
 Lucretia A. Risoleo
 Dr. Richard S. Rivlin
 The Robbins Family Foundation, Inc.
 Robbins Foundation
 James Robertson
 Karen Robertson, MD '75
 James C. Robinson
 Mr. and Mrs. Alexander Roepers
 Howland P. Rogers
 The Rogosin Institute
 Roisen Family Foundation
 Harold R. Ronson Trust
 Mr. and Mrs. Leonard M. Rosen
 Thomas Jefferson Rosenberg Foundation
 Lief D. Rosenblatt
 Milton B. Rosenbluth Foundation
 Dr. Lynda E. Rosenfeld
 The Rosenfeld Heart Foundation, Inc.
 Elizabeth and Robert Rosenman Charitable Foundation
 Arnold I. Rosenshein
 Harry and Andrew H. Rosenthal Foundation
 Carol Rosenwald
 The Edward John & Patricia Rosenwald Foundation
 William Rosenwald Family Fund
 Ruth and Samuel J. Rosenwasser Charitable Trust
 Philip Ross
 Dr. and Mrs. Kenneth O. Rothaus
 Joan O. Rothberg
 Fred and Frances Rothstein
 Mr. and Mrs. James T. Rothwell
 James R. Rowen
 Mr. and Mrs. Andrew S. Rowen
 RTR Financial Services, Inc.
 The Lawrence Ruben Foundation
 Selma Ruben Foundation
 Rubenstein Associates, Inc.
 Barbara Rubin Charitable Trust
 Eric I. Rubin
 Mr. and Mrs. LeRoy Rubin
 Philip S. Rubin
 Dr. Stuart J. Rubin
 Mr. and Mrs. Jerold Ruderman
 Eric C. Rudin
 Louis and Rachel Rudin Foundation
 Margery and Stephen Russell
 Paul S. Russell
 Estate of Sarah de C. Ruth
 S L Green Management, LLC
 S. Forest Company, Inc.
 Peter M. Sacerdote Foundation
 Mr. and Mrs. David Sachs
 Raymond and Beverly Sackler Foundation (UK)
 Edmond Moise Safra
 Jacob Moise Safra
 Mr. and Mrs. Stuart M. Saft
 Dmitry L. Sagalovskiy
 Janet Saint Germain
 Irving Salem
 The Jack & Anita Saltz Foundation, Inc.
 Henry Salzhauer
 Marilyn J. Samuels
 Barbara S. Samuelson
 The San Diego Foundation
 Sanofi-Aventis, U.S., Inc.
 Sass Foundation for Medical Research
 Dr. John J. Savarese
 Jed David Satow Family Foundation
 Richard Savitt
 Mark H. Sayers
 Ann C. Scavullo
 Gretchen S. Schacht
 Wendy Schaenen, MD
 Larry Schafer
 Schaffer, Schonholz & Drossman, LLP
 Dr. and Mrs. Fred Schecter
 J. Lew Schepps
 Dr. Ellen J. Scherl
 Dr. Lawrence Scherr
 Scheuer Associates Foundation, Inc.
 Schindler Elevator Corporation
 Ottilie Schmid-Sanders
 Mr. and Mrs. Richard F. Schmidt
 Nancy & John Schneider Foundation
 Mr. and Mrs. Irwin Schneiderman
 Mr. and Mrs. Peter Schoenfeld
 School Food Service Papoos Restaurant
 Carole and Alvin Schragis
 Dr. Theodore L. Schreiber
 The Schreyer Foundation
 Dr. Michael Schulder
 Mr. and Mrs. Michael P. Schulhof
 The Schulhof Family Foundation
 Schwab Charitable Fund
 Dr. Mark H. Schwartz
 Mr. and Mrs. Max J. Schwartz
 Rochelle Schwarz
 Barbara J. Scott
 Thomas P. Sculco, MD
 Sealcoating, Inc.
 Lucille Sedgeley
 Douglas Sedgwick
 The Ivan Seidenberg Foundation, Inc.
 Select Anesthesia and Pain Management Group, Pa.
 Dr. Samuel H. Selesnick
 Florence E. Sell
 Izak Senbahar
 Audrey Sevin

Mel A. Shaftel
Gregory Shaia
Joseph Shapiro
Sidney Shapiro
Shapiro-Silverberg Foundation
Ashley Share
Dr. and Mrs. David E. Shaw
The Shaw Family Endowment Fund
Howard W. Shawn
Barbara Sheib
The Shepherd Foundation
Mr. and Mrs. David M. Sherman
Mr. and Mrs. Mark H. Sherman
Mr. and Mrs. Peter D. Sherman
Dr. Chun-Jen Shih
Naoki Shimada
Michael R. Shraga
Lee P. Shulman, MD '83
Rena Shulsky
John D. Sicher
Jesse and George Siegel Foundation
Mr. and Mrs. Herbert J. Siegel
Signature Bank
Sikelia Productions, Inc.
Joachim Silberman Family
Lois V. Silberman
M. Steven Silbermann
Rosanne Silbermann
Dr. Richard T. Silver
The Silvercrest Center for Nursing &
Rehabilitation
Jeffrey Silvershein
The Simmons Family Foundation
Talbot and Carter Simonds
Foundation
Carl and Fay Simons Family
Charitable Trust II
Estate of Alexandrine Sinsheimer
Donald G. Skinner, MD
S-L Marketing Specialist, Inc.
Alan B. Slifka Foundation
Joseph and Sylvia Slifka Foundation
Smart Solutions for Health Care
Mr. and Mrs. A. J. C. Smith
Mr. and Mrs. David T. Smith
Dr. Kenneth R. Smith Jr.
Ian and Margaret Smith Family
Foundation
Dr. and Mrs. Robert B. Snow
Susan Solomon
Solomon Family Foundation, Inc.
Mr. and Mrs. Barrie Sommerfield
Dr. Emily B. Sonnenblick
The Sontheimer Foundation
Paul and Daisy Soros Foundation
Isaac R. Souede
Norton Sperling
Gary N. Spero Community Mental
Health Foundation
The Speyer Family Foundation
Gilbert S. Spitzer
The Seth Sprague Educational and
Charitable Foundation
St. Giles Foundation
The Stamford Hospital
Benjamin F. Stapleton
Starbound National Talent
Competition
Stark, Armon & Liner, LLP
The Starr Foundation
Estate of Leopoldine Stehno
Dr. Sidney F. Stein
The Fred Stein Family Foundation
Dr. Charles R. Steinberg
Dr. Ladislau E. Steiner
Dr. Kurt H. Stenzel
Beatrice Stern
Howard A. Stern
Mr. and Mrs. Howard N. Stern
Miriam Stern
The Stern Trust
Mrs. Richard Sterne
Estate of Josephine Stetson
Justin A. Stevens
Patricia Carry Stewart
Mr. and Mrs. Ronald P. Stewart
Susan C. Stewart, MD
John W. & Laura Stewart
Foundation, Inc.
The Stone Foundation, Inc.
Stony Point Foundation
The Storch Foundation
Dr. Carol L. Storey-Johnson
Karl Storz Endoscopy-America,
Inc.
Robert L. Stott Foundation
Estate of May Strang
Loretta M. Stratton
Strausman Family Fund, Inc.
Nancy Angell Streeter
Howard Stringer
Stroock & Stroock & Lavan
Everett D. & Geneva V.
Sugarbaker Foundation
Eleanor Sullivan
Patricia C. Sullivan
Aron L. Suna
Sunbelt Beverage Company, LLP
Suskram Family Foundation
Dr. Kenneth G. Swan
Christopher Swartout
The Sweet Peas Foundation
Nan and Stephen Swid
Mr. and Mrs. Eric Rosen
Virginia A. Swift
Dr. Alexander J. Swistel
Synovis Surgical Innovations
Synthes Spine Co., LP
Syska & Hennessy
Sysmex Corporation of America
Mr. and Mrs. John A. Syverson
Dr. Hazel H. Szeto
J. T. Tai & Company Foundation,
Inc.
Dr. Kenneth C. Tam
Tams-Witmark Music Library
Susan Jaffe Tane
Dr. and Mrs. Stephan B. Tatter
Anne R. Taylor Living Trust
Mr. and Mrs. Paul D. Taylor
Topsey Taylor
Dr. Alexis E. Te
Vincent and Joyce Tese
Allan R. Tessler
Mr. and Mrs. Lenard Tessler
Teva Neuroscience, Inc.
Arbie R. Thalacker
Dr. James M. Theil
Mr. and Mrs. Charles W. Thomas
Tibotec Therapeutics
The Tinker Foundation,
Inc.
Tishman Construction Corporation of
New York
The TLM Group, LLC
Tobacco Control Research &
Education Foundation
Barbara and Donald Tober
Foundation
Mr. and Mrs. H. James Toffey
Dr. Allen J. Togut
Marilyn Tomack Charitable Remainder
Unitrust
Michael Tomasko IV
Jay Topkis
Dr. Anthony J. Tortolani
Dr. Richard E. Tosi
Treibick Family Foundation
Marc R. Trevino
Triarc Companies
Sandra L. Tsang-Cohen
Dr. James J. Turro
Tyco Healthcare
Unilever United States Foundation,
Inc.
United Way of Tri-State
United Way of New York City
The Adam Usdan 2004 C.L.A.T.
USGI Medical, Inc.
Dr. Frederick W. Van Duyn III
Leo Van Munching Jr.
The Vanguard Charitable Endowment
Program
Verizon Foundation
Vermont Community Foundation
Estate of Elsie Vinik
Estate of Tolly Vinik
Visiting Nurse Service of New York
Vital Projects Fund, Inc.
Vivendi Universal
Voices Against Brain Cancer, Inc.
Mr. and Mrs. William Von Mueffling
Ashley R. Von Perfall
Dr. Rand M. Voorhies
Mr. and Mrs. Chris Vulliez
Wadler Family Trusts
Charles E. Wainhouse
William P. Waldron
Mr. and Mrs. C. Carter Walker Jr.
Joann B. Walker
David W. Wallace Foundation
Mr. and Mrs. Ira D. Wallach
Nicholas W. Walsh
Walters Charitable Trust
Mr. and Mrs. Charles G. Ward III
John L. Warden
Thomas Warfield
Washington Mutual Bank
Dr. Raymond V. Wedderburn
Mr. and Mrs. William M. Weiant
Florence Weicker
Joan and Sanford I. Weill
Monique Weill-Caulier Trust
Mr. and Mrs. Kenneth J. Weiller
Sue Ann Weinberg
The Weinberg Family Foundation
The John S. & Amy S. Weinberg
Foundation
The Sue Ann & John L. Weinberg
Foundation
Gary R. Weine, MD '76
Sara and Scott Weiner
Dr. Gail G. Weinmann
Eric W. Weinmann Charitable
Lead Annuity Trust
Don Weinreich
Steven Lloyd Weinrib Charitable
Foundation
Irving Weinstein Foundation, Inc.
Joyce-Marie Weinstein Revocable
Trust
Arthur M. Weis
The Carol & Michael Weisman
Family Charitable Trust
Peter Weiss
Mrs. Stephen H. Weiss
Roger Weiss Family Foundation
The Stephen and Suzanne Weiss
Foundation
The Joyce & Gary Wenglowksi
Foundation
Nina W. Werblow Charitable Trust
Eugene Wexler
Mrs. William O. Wheatley
White Plains Hospital
Helene Whitman Memorial
Cancer Fund
Mr. and Mrs. Malcolm Wiener
The Malcolm Hewitt Wiener
Foundation
Mr. and Mrs. Paul D. Williams
Tanya Williams
William J. Williams Jr.
William E. Willis
Dr. Philip J. Wilner
Dr. Philip D. Wilson Jr.
The Winston Foundation
Winston & Strawn, LLP
Winston Resources, LLC
Elizabeth Heyman Winter
Wisch Family Foundation
The Meryl & Charles Witmer
Charitable Foundation
Diane and Howard Wohl Family
Foundation
David J. Wolf, MD
Alexander Wolf & Son
Wolfensohn Family Foundation
Marc Wolfson
The Michael Wolk Heart
Foundation
John E. Wong
Dr. Francis A. Wood
Suzanne Wright
Lester Wunderman
Wyckoff Heights Medical Center
Elaine F. Yaniv
Richard Yau
Helena Tse Yeung Foundation
Dr. Robert C. Young
Robert Zanger
Zankel Fund
Marjorie Zickel
Dr. Robert E. Zickel
Mr. and Mrs. Victor Zonana

If you have questions or corrections, please contact the Development Office at 800-345-3015. We regret any errors or omissions.

Save the Date

WCMC-Q maps the genome of the Middle East's signature crop

Dates are to the Middle East what apples are to America—not only a staple crop but a cultural symbol. So when researchers at Weill Cornell Medical College in Qatar cast about

for a plant with which to test the capabilities of their new Genomics Laboratory, they didn't have to look far. "It's such an important crop in this part of the world, because it's one of the few trees that can withstand the environment—extreme heat, wind, sandstorms—and still produce nutritious fruit," says Joel Malek, MS, the lab's director. "It's one of those crops that the rest of the world would not necessarily be interested in studying. But historically, this region has relied heavily on dates in all kinds of ways."

In February, Malek and a team of four technicians began unraveling the secrets of the date palm using the latest technology, known as next-generation DNA sequencing. While such technology has generally been used for resequencing—in which researchers already have a reference and are looking for small differences between samples—using it to map a genome from scratch was uncharted territory. Of the 3,000 varieties of date, they chose the Khalas (*Phoenix dactylifera*), considered one of the finest. "Apparently it's the quintessential date, not too sweet or salty," says Malek, a native of the Boston area who has developed an appreciation for the fruit in the year and a half he's been in Doha. "It has just the right flavor, and because of that it's expensive. Now, when

Tree of life: The date palm, seen in an eighteenth-century illustration, has been a vital crop in the Middle East for millennia.

I go to the store I keep my eye out for it."

Although the date palm genome is small compared to that of other plants, it still comprises about 300 million bases—only about 3,000 of which had previously been sequenced. But within a few months, the researchers announced that they had completed a draft of the genome. They're currently preparing their work for

publication and will continue the project as funding becomes available. "We've probably decoded 90 to 95 percent of the 300 million bases, and we know what their general neighborhood is," Malek says. "We have the sequence, but where exactly the genes sit on the genome and in what order—we have a rough view of that."

The work, Malek says, could offer major advances in the ancient practice of date cultivation—particularly in making them hardier. "A lot of domesticated date palms are not very resistant to disease, whereas wild trees are," he says. "We're trying to figure out why. Have the ones that have been cultivated for thousands of years lost certain immunity genes?" The research could also facilitate propagation. Date palms come in male and female versions, with only the latter producing fruit; growers need a single male to pollinate every fifty to one hundred females. To ensure the right balance, they can't just plant from seed; they have to wait for a female tree to sprout a shoot, allow it to grow for several years, then transplant it. "It's decades before they can regenerate an orchard," Malek says. "Our

goal would be to find the genetic difference between male and female and come up with a test for the seeds."

In addition to aiding local agriculture, the date palm project was launched to prove the capabilities of the biomedical research program at WCMC-Q. The program is funded by support from the Qatar Foundation, which aims to make it a hub for research throughout the Middle East. "Many people don't set out to do these larger projects because they don't believe the technology exists here," Malek says. "The goal is to get the country and the region up to speed. Because once people see that it can be done, they'll start envisioning what they could accomplish."



FROM: A CURIOUS HERBAL, ELIZABETH BLACKWELL, 1737

A TIME OF HOPE


The holiday season is a time of celebration, expectation, and a measure of the promise of things to come.

There has been much to celebrate over this past year, including recognition of the research spearheaded by our basic science and clinical faculty in the form of new and renewed contracts and grants during an increasingly difficult time of constrained federal resources. But in the face of a struggling economy, our donors have continued to step forward to ensure that we will continue our mission of unexcelled medical education and breakthrough research, both contributing to a pledge to provide the highest quality patient care. Our new Medical Research Building will serve as a cornerstone for our future as a world-renowned “bench to bedside” institution. One can only look to the future with much hope and expectation.

*Wishing you peace and good health
in the year ahead,*

Antonio M. Gotto

Dean Antonio M. Gotto Jr.



RENDERING © REDSQUARE, INC. FOR POLSHEK PARTNERSHIP ARCHITECTS



Weill Cornell Medical College

DISCOVERIES
THAT MAKE A DIFFERENCE
THE CAMPAIGN FOR WEILL CORNELL MEDICAL COLLEGE

Weill Cornell Medical College and
Weill Cornell Graduate School of Medical Sciences
1300 York Avenue, Box 144
New York, NY 10065

Address Service Requested

PRSRT STD
US Postage
PAID
Permit 302
Burl., VT. 05401

FAMILY DAY 2010



SAVE THE DATE Friday, March 26, 2010



Weill Cornell Medical College